


13. | 2. | 2024  
cilt | sayı | ağustos  
volume | issue | august

ISSN: 1305-4392  
e-ISSN: 2147-1800

# Abant Tıp Dergisi (abantmedj)

Abant Medical Journal



# Abant Tıp Dergisi

## Abant Medical Journal

Cilt/Volume:12 Sayı/ Issue: 2 - Nisan / April 2023  
e-ISSN: 2147-1800

### SAHİBİ / OWNER

**Prof. Dr. Gürkan Öztürk** - abantmedj@ibu.edu.tr  
Dean of Medical Faculty of Bolu Abant İzzet Baysal University, Bolu - Türkiye

### BİLİMSEL YAYIN VE DERGİLER KOORDİNATORLÜĞÜ / SCIENTIFIC PUBLICATIONS AND JOURNALS COORDINATOR

**Assoc. Prof. Dr. Mustafa YİĞİTOĞLU** - mustafayigitoglu@ibu.edu.tr  
Coordinator, Bolu Abant İzzet Baysal University, Bolu - Türkiye

**Assist. Prof. Dr. Can DOĞAN** - can.dogan@ibu.edu.tr  
Coordinator Assistant, Bolu Abant İzzet Baysal University, Bolu - Türkiye

**Assoc. Prof. Dr. Fatma DEMİRAY AKBULUT** - demiray\_f@ibu.edu.tr  
Coordinator Assistant, Bolu Abant İzzet Baysal University, Bolu - Türkiye

### BAŞ EDİTÖR/ EDITOR IN CHIEF

**Assoc. Prof. Dr. Murat ALIŞIK** - muratalisik@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Medical Biochemistry, Bolu - Türkiye

### BAŞ EDİTÖR YARDIMCILARI/ DEPUTY EDITOR IN CHIEF

**Uzm. Dr. Faruk DANIŞ** - farukdanis@gmail.com  
Bolu İzzet Baysal Training and Research Hospital, Department of Emergency Medicine, Bolu – Türkiye

### ALAN EDİTÖRLERİ/ FIELD EDITORS

- Prof. Dr. Akif Hakan KURT**- hakankurt@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Department of Medical Pharmacology, Bolu – Türkiye
- Prof. Dr. Ash ÇELEBİ TAYFUR**- asli.celebitayfur@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Child Health and Diseases, Bolu – Türkiye
- Prof.Dr. FAHRİ BAYIROĞLU** - fbayiroglu@yahoo.com  
Ankara Yıldırım Beyazıt University, Faculty of Medicine, Department of Physiology, Ankara, Türkiye
- Prof. Dr. İbrahim EREN** - ibrahimeren@sdu.edu.tr  
Suleyman Demirel University, Faculty of Medicine, Department of Psychiatry, Isparta -Türkiye
- Prof. Dr. Mahmoud MUSTAFA** - m.al-mustafa@ju.edu.jo  
An-najah National University, Medical Faculty, Department of Urology, Nablus, Palestine
- Prof. Dr. Mehmet TAŞPINAR** - mtaspinartr@gmail.com  
Aksaray University, Faculty of Medicine, Department of Medical Biology, Aksaray, Türkiye
- Assoc. Prof. Dr. Akif GÜNEŞ** - akif.gunes@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Department of Otorhinolaryngology, Bolu – Türkiye
- Assoc. Prof. Dr. Ayşegül DANIŞ**- ayseguldanis7@gmail.com  
BAIBU İzzet Baysal Training and Research Hospital, Pediatric Neurology, Bolu – Türkiye
- Assoc. Prof. Dr. Elif YAKŞI** - elifyaksi@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Bolu - Türkiye
- Assoc. Prof. Dr. Emrullah SÖĞÜTDELEN** - emrullahsogutdelen@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Urology, Bolu - Türkiye
- Assoc. Prof. Dr. Eşref ARAÇ** - esrefarac@gmail.com  
Department of Internal Medicine, Health Sciences University Gazi Yasargil Training and Research Hospital, Diyarbakır, Türkiye
- Assoc. Prof. Dr. Fatma AVCIOĞLU** - fatmaavcioglu@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Medical Microbiology, Bolu – Türkiye
- Assoc. Prof. Dr. Fikret SALIK** - fikretsalik@gmail.com  
Gazi Yasargil Training and Research Hospital, Department of Anesthesiology and Reanimation, Diyarbakır, Türkiye
- Assoc. Prof. Dr. Güray CAN** - dr\_guraycan@yahoo.com  
Bursa Özel Doruk Yıldırım Hastanesi, Bursa - Türkiye
- Assoc. Prof. Dr. Mehmet Özgür YİS** - ozgurmehmetyis@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Medical Biochemistry, Bolu – Türkiye
- Assoc. Prof. Dr. Mehmed Uğur İŞİK** - mehmedugur@windowslive.com  
Kastamonu University, Faculty of Medicine, Department of Ophthalmology, Kastamonu -Türkiye
- Assoc. Prof. Dr. Murat YILMAZ** - murat.yilmaz@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Neurology, Bolu – Türkiye
- Assoc. Prof. Dr. Nadire KÜÇÜKÖZTAŞ** - nadire.kucukoztas@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Internal Medicine, Bolu - Türkiye
- Assoc. Prof. Dr. Sebahat GÜCÜK** - sebahatgucuk@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Family Medicine, Bolu – Türkiye
- Assoc. Prof. Dr. Semih BOLU** - semih.boluibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Department of Child Health and Diseases, Bolu - Türkiye
- Assoc. Prof. Dr. Tacettin AYANOĞLU** - tacettinayanoglu@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Orthopedics and Traumatology, Bolu – Türkiye
- Assoc. Prof. Dr. Tayibe BAL** - dr.tayibal@gmail.com  
Bolu Abant İzzet Baysal University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Bolu, Türkiye

**Assoc. Prof. Dr. Tuba TASLAMACIOĞLU DUMAN** - tubaduman@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Internal Medicine, Bolu – Türkiye  
**Assist. Prof. Dr. Ali Can ÖNAL** - acan.onal@beun.edu.tr  
Zonguldak Bülent Ecevit University, Faculty of Medicine, Medical Pathology, Zonguldak – Türkiye  
**Assist. Prof. Dr. Mustafa BAKIRCI** - mustafa.bakirci@bozok.edu.tr  
Yozgat Bozok University, Faculty of Medicine, Department of Obstetrics and Gynecology, Yozgat – Türkiye  
**Assist. Prof. Dr. Mustafa Enes DEMİREL** - mustafaenesdemirel@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Emergency Medicine, Bolu - Türkiye  
**Assist. Prof. Dr. Samet ŞAHİN** - sametsahin@mu.edu.tr  
Muğla Sıtkı Koçman University, Department of General Surgery, Muğla -Türkiye  
**Assist. Prof. Dr. Tuğba ALIŞIK** – dr.tugbaakkoyun@hotmail.com  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Bolu - Türkiye  
**Assist. Prof. Dr. Yunus YILMAZSOY**- yunusyilmazsoy@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Radiology, Bolu – Türkiye  
**Uzm. Dr. Emre KUDU** - dr.emre.kudu@gmail.com  
Marmara University Pendik Training and Research Hospital, Department of Emergency Medicine, İstanbul - Türkiye

#### **YAYIN KURULU / EDITORIAL BOARD**

**Prof. Dr. Akif Hakan KURT**  
Bolu Abant İzzet Baysal University Faculty of Medicine, Department of Medical Pharmacology, Bolu – Türkiye  
**Prof. Dr. Ali KILIÇGÜN**  
Bolu Abant İzzet Baysal University Faculty of Medicine, Department of Thoracic Surgery, Bolu – Türkiye  
**Prof. Dr. Fatma TÖRE**  
Biruni University, Faculty of Medicine, Department of Physiology, İstanbul - Türkiye  
**Prof. Dr. Fuat AKPINAR**  
İstanbul Medeniyet University, Faculty of Medicine, Department of Orthopedics and Traumatology, İstanbul - Türkiye  
**Prof. Dr. Mehmet ÖZDEMİR**  
Necmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Microbiology, Ankara – Türkiye  
**Prof. Dr. Mustafa ŞİT**  
Bolu Abant İzzet Baysal University Faculty of Medicine, Department of General Surgery, Bolu – Türkiye  
**Prof. Dr. Muzaffer KIRIŞ**  
Health Sciences University Gülhane Faculty of Medicine, Department of Otorhinolaryngology, Ankara - Türkiye  
**Prof. Dr. Ömer ANLAR**  
Ankara Yıldırım Beyazıt University, Faculty of Medicine, Department of Neurology, Ankara – Türkiye  
**Prof. Dr. Safiye GÜREL**  
Gülhane Training and Research Hospital, Department of Radiology, Ankara - Türkiye  
**Prof. Dr. Seyit Ali KAYIŞ**  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Biostatistics, Bolu - Türkiye  
**Prof. Dr. Yusuf Özgür BİÇER**  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Otorhinolaryngology, Bolu – Türkiye  
**Assoc. Prof. Dr. Mehmet Özgür YİS**  
Bolu Abant İzzet Baysal University Faculty of Medicine, Department of Medical Microbiology, Bolu – Türkiye  
**Assist. Prof. Dr. Hamdi AFŞİN**  
Bolu Abant İzzet Baysal University Faculty of Medicine, Department of Nuclear Medicine, Bolu – Türkiye  
**Assist. Prof. Dr. Mustafa BAKIRCI**  
Yozgat Bozok University, Faculty of Medicine, Department of Obstetrics and Gynecology, Yozgat – Türkiye  
**Dr. Khadijeh TAIYARI**  
Cardiff University, Centre for Trials Reserach, Cardiff- Galler  
**Dr. Muhammad AKHLAQ**  
Gomal University, Faculty of Pharmacy, Department of Pharmacognosy, Dera Ismail Khan – Pakistan

#### **İNGİLİZCE DİL EDİTÖRLERİ / ENGLISH LANGUAGE EDITORS**

**Prof. Dr. İbrahim KÜRTÜL** - ibrahimkurtul@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Anatomy, Bolu - Türkiye  
**Assist. Prof. Dr. Ömür Gülsüm DENİZ** - omur.deniz @ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Histology and Embryology, Bolu – Türkiye

#### **İSTATİSTİK EDİTÖRLERİ / STATISTICAL EDITORS**

**Assist. Prof. Dr. Oya KALAYCIOĞLU** - oyakalaycioglu@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Department of Biostatistics, Bolu - Türkiye

#### **YAYIN EDİTÖRÜ, MİZANPAJ EDİTÖRÜ / BROADCAST EDITOR, LAYOUT EDITOR**

**Lecturer Adnan ŞEN** – adnan@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Information Technology, Bolu – Türkiye

#### **TEKNİK EDİTÖR, WEB EDİTÖRÜ / TECHNICAL EDITOR, WEB EDITOR**

**Lecturer Adnan ŞEN** – adnan@ibu.edu.tr  
Bolu Abant İzzet Baysal University, Faculty of Medicine, Information Technology, Bolu – Türkiye

## HAKEM KURULU / REFEREE BOARD

**Abant Tıp Dergisi [Abantmedj]**, en az iki hakemin görev aldığı çift taraflı kör hakemlik sistemi kullanmaktadır. Hakem isimleri gizli tutulmakta ve yayımlanmamaktadır. / **Bu konuda genel bilgi için** <https://dergipark.org.tr/tr/pub/abantmedj>  
**Abant Medical Journal [Abantmedj]** uses double-blind review fulfilled by at least two reviewers. Referee names are kept strictly confidential. **For detailed information, please click here:** <https://dergipark.org.tr/tr/pub/abantmedj>

## ADRES/ADDRESS

Abant Tıp Dergisi Editörlüğü  
Bolu Abant İzzet Baysal Üniversitesi Tıp Fakültesi Dekanlığı 14030 BOLU - TÜRKİYE  
Tel: +90 374 253 46 56 Faks: +90 374 253 45 59  
e-posta: [abantmedj@ibu.edu.tr](mailto:abantmedj@ibu.edu.tr)  
Web: <https://dergipark.org.tr/tr/pub/abantmedjkaqmu> sm


## COPYRIGHT AND LICENSE




Abant Medical Journal is licensed under a [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License](https://creativecommons.org/licenses/by-nc-nd/4.0/).  
Abant Tıp Dergisi [Creative Commons Atıf-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı](https://creativecommons.org/licenses/by-nc-nd/4.0/) ile lisanslanmıştır.

## DİZİNLENME BİLGİLERİ / ABSTRACTING AND INDEXING SERVICES

**Abant Tıp Dergisi**, Türk Medline, Sobiad Atıf Dizini, Google Scholar, TR Dizin (2013 - 2015 yılları arası) tarafından taranmaktadır.

 **Abant Tıp Dergisi (Abantmedj)**, sağlık bilimlerindeki tüm etik yönergelere uygun olarak hazırlanmış klinik ve deneysel araştırma makaleleri, olgu bildirimleri, derleme makaleleri, teknik notlar ve editöre mektupları yayınlamaktadır. Abant Tıp Dergisi Bolu Abant İzzet Baysal Üniversitesi Tıp Fakültesi'nin resmi yayın organı olan bir dergidir. Yılda 3 sayı halinde (Nisan, Ağustos, Aralık) elektronik ortamda yayınlanır. Derginin resmi yayın dili Türkçe ve İngilizce'dir. Dergimiz "Şeffaflık ve Akademik Yayıncılık En İyi Uygulamalar İlkelerine" (Principles of Transparency and Best Practice in Scholarly Publishing) ([doaj.org/bestpractice](https://doaj.org/bestpractice)) uygun olarak yayınlanmaktadır. Yayımlanan yazıların bütün yayın hakları **Abantmedj**'e ait olup, yayıncının izni olmadan kısmen veya tamamen basılamaz, çoğaltılamaz ve elektronik ortama taşınmaz. Yazıların yayımlanıp yayımlanmamasından yayın kurulu sorumludur."

 **Abant Medical Journal (Abantmedj)**, publishes all forms of clinical and research articles prepared in line with all ethical principles in the health sciences, case reports, review articles, technical notes, and letters to the editor. The Abant Medicine Journal is the official publishing organ of the Bolu Abant İzzet Baysal University Faculty of Medicine. It is published electronically three times a year (in April, August, and December). The journal's official languages are Turkish and English. It is published in accordance with the 'Principles of Transparency and Best Practice in Scholarly Publishing' ([doaj.org/bestpractice](https://doaj.org/bestpractice)). Published texts belong to abantmedj, and cannot be published partly or in full, reproduced, or transferred to an electronic environment without permission. The responsibility for whether or not texts should be published lies with the editorial board."

## İçindekiler / Contents

i-iv | **Jenerik / Generic**

### Editöre Mektup / Letter to Editor

---

- 45-46 | **A Call for Innovation in Drug Screening: Integrating Genetically Encoded Biosensors for Deeper Insights**  
İlaç Taramasında Yenilik Çağrısı: Daha Derin Bilgiler İçin Genetik Olarak Kodlanmış Biyosensörlerin Entegrasyonu  
Emrah EROĞLU

### Araştırma Makalesi / Research Article

---

- 47-53 | **Evaluation Of Plummer-Vinson Syndrome in Pediatric Patients with Dysphagia**  
Disfaji Olan Çocuk Hastalarda Plummer-Vinson Sendromunun Değerlendirilmesi  
Sevinç Garip
- 54-60 | **Retrospective Comparison of Talon or Conventional Locking Nailing for Tibial Shaft Fractures**  
Tibia Gövde Kırıklarında Talon ve Geleneksel Kilitli Çivilemenin Retrospektif Karşılaştırması  
Fatih GÜNAYDIN, Öner KILINÇ, Bülent SAKARYA, Yusuf BAYRAM
- 61-68 | **COVID-19 Pneumonia-Related ARDS – Can We Predict Mortality with Laboratory Parameters?**  
COVID 19 Pnömonisi Sonrası Gelişen ARDS'de Laboratuvar Parametreleri Mortaliteyi Öngörmeye Kullanılabilir Mi?  
Musa KAYA, Derya KOCADAĞ, Zeynep BAYSAL
- 69-79 | **Comparison Of Three Methods for Calculation of Sacroiliac Joint Index in Different Age Groups in Bone Scintigraphy**  
Kemik Sintigrafisinde Farklı Yaş Gruplarında Sakroiliak Eklem İndeksinin Hesaplanmasında Kullanılan Üç Yöntemin Karşılaştırılması  
Ebru SALMANOĞLU

### Olgu Sunumu / Case Report

---

- 80-84 | **Revision of The Total Hip Arthroplasty Previously Placed False Acetabulum**  
Yalancı Asetabulumuna Yerleştirilen Total Kalça Artroplastisinin Revizyonu  
Mahmut KURTBOĞAN, Cengiz IŞIK, Cemal ALKAN, Mahmut Timur TURHAN
- 85-93 | **Ceftazidime-induced Non-Convulsive Status Epilepticus (NCSE) in a pediatric patient with Literature Review**  
Pediatrik Hastada Seftazidime Bağlı Nonkonvülsif Status Epileptikus (NKSE) Olgusu; Seftazidime Bağlı NKSE  
Mehpare Sarı YANARTAŞ, Sait AÇIK, Özlem YAYICI KÖKEN, Gülşah AKSOY, Şenay HASPOLAT
- 94-97 | **A Case Report: Lipomatous Hypertrophy of the Interatrial Septum**  
Olgu Sunumu: İnteratriyal Septumun Lipomatöz Hipertrofisi  
Ayşenur Buz YAŞAR, Sıddıka HALICIOĞLU



# Abant Tıp Dergisi

## Abant Medical Journal

Abant Med J 2024;13(2):45-46, doi:10.47493/abantmedj.1529498



### A Call for Innovation in Drug Screening: Integrating Genetically Encoded Biosensors for Deeper Insights

İlaç Taramasında Yenilik Çağrısı: Daha Derin Bilgiler İçin Genetik Olarak Kodlanmış Biyosensörlerin Entegrasyonu

Emrah EROĞLU <sup>1\*</sup>

<sup>1</sup>Istanbul Medipol University, Faculty of Pharmacy, Istanbul, Türkiye

Geliş Tarihi (Received): 07.08.2024

Kabul Tarihi (Accepted): 18.08.2024

Yayın Tarihi (Published): 29.08.2024

Dear Editor,

We are writing to express our views on the urgent need for more informative and efficient methods in drug screening and testing within preclinical and translational medicine. The current state of the art primarily involves 2,5-diphenyl-2H-tetrazolium bromide (MTT) or similar cell viability assays, which provide limited information, predominantly focusing on cell toxicity. These methods are poor in providing insights into specific cellular mechanisms, long-term effects, or the drug's mode of action, thereby failing to deliver the comprehensive analysis required in modern drug development (1).

In vivo experiments, specifically in the context of drug development, are increasingly being abandoned in both the EU and the USA due to ethical concerns and regulatory changes. As a result, the reliance on in vitro systems and the development of innovative tools for drug screening have become more crucial than ever. Among these, genetically encoded biosensors for high-content drug screening represent a highly promising yet underutilized approach in the field.

Genetically encoded biosensors are advanced tools designed to provide real-time insights into cellular processes. Engineered from natural or synthetic genetic elements, these biosensors are optimized for high-throughput applications, allowing detailed monitoring of cellular responses. They track various biological signals or molecules, offering precise data on drug mechanisms and interactions at the molecular level (2). Integrating these biosensors into drug screening protocols can significantly enhance the efficiency and effectiveness of drug development processes by providing critical, functional insights into how drugs impact cellular functions.

Some of our previous studies have highlighted the significant value and effectiveness of genetically encoded biosensors in this field. These biosensors have proven particularly valuable in studying nitric oxide (NO), a crucial signaling molecule in the cardiovascular system (3). NO is essential for regulating vascular tone, blood pressure, and overall cardiovascular health by activating soluble guanylate cyclase (sGC), leading to vasodilation and maintaining endothelial function and vascular homeostasis. In the context of cardiovascular therapeutics, nitroglycerin (GTN) is a well-established antianginal drug that exerts its effects through NO release. The bioactivation of GTN by aldehyde dehydrogenase-2 (ALDH2) converts it to NO, which then activates sGC and induces vasodilation. Despite GTN's clinical success, understanding the precise mechanisms of its NO release and its impact on NO signaling pathways has been challenging due to limitations in traditional measurement techniques. Our research has demonstrated how advancements in genetically encoded biosensors can overcome these challenges. These innovative tools provide important insights into the real-time dynamics and spatial distribution of NO within cells, enabling a more precise visualization of NO production and its effects on cellular signaling. Our study, employing NO biosensors, has notably advanced the understanding of NO's role in cardiovascular pharmacology.

**Atıf/Cite as:** Eroğlu E. A Call for Innovation in Drug Screening: Integrating Genetically Encoded Biosensors for Deeper Insights. Abant Med J. 13(2):96-97. doi:10.47493/abantmedj.1529498

\*Sorumlu Yazar (Corresponding Author): Emrah Eroğlu, e-mail: emrah.eroglu@medipol.edu.tr



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.



It has addressed longstanding questions about NO signaling in response to GTN, highlighting the intricate interplay between drug metabolism and NO production in the vascular system (4).

In another study, we assessed the efficacy of two approved iron supplement drugs – Venofer and Ferinject – using our genetically encoded biosensor approach. This method effectively detects available iron (II) in cultured cells, demonstrating that genetically encoded biosensors are valuable tools for drug screening and testing at the (sub)cellular level (5).

Another crucial point we address is the critical importance of physiological oxygen levels in drug testing. We discovered that cells cultured under physiological normoxia (5 kPa O<sub>2</sub>) require notably lower iron supplementation to activate metalloproteins compared to cells grown in standard room air (18 kPa O<sub>2</sub>) (6). Additionally, we used genetically encoded biosensors to investigate the complex interaction between hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and nitric oxide (NO) in endothelial cells under varying oxygen conditions. Traditionally, simultaneous measurement of these molecules has been technically challenging, leading to inconsistent results. By employing advanced biosensors -HyPer7 for H<sub>2</sub>O<sub>2</sub> and geNOps for NO- for concurrent imaging in single cells, we found that, under ambient oxygen conditions, H<sub>2</sub>O<sub>2</sub> did not significantly impact NO production. However, under physiological normoxia, we observed distinct oxidative stress and nuanced NO responses to H<sub>2</sub>O<sub>2</sub> (7). These results underscore the necessity of incorporating physiological conditions into cellular studies to obtain accurate, meaningful insights, thereby enhancing the reliability of drug testing protocols.

We believe that integrating genetically encoded biosensors into standard drug screening protocols could significantly enhance the development of safer and more effective therapeutics. Their ability to provide detailed functional insights at the cellular level addresses a critical gap left by traditional drug testing methods.

Thank you for considering our perspectives on this matter. We look forward to further discussions and collaborations to advance the field of drug screening and testing.

Sincerely,

**Informed Consent:** Written consent was obtained from the participants.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors declared no financial support.

**Author Contributions:** Idea/Concept: E.E.; Design: E.E.; Supervision: E.E.; Funding: E.E.; Materials: E.E.; Data Collection/Processing: E.E.; Analysis/Interpretation: E.E.; Literature Review: E.E.; Drafting/Writing: E.E.; Critical Review: E.E. The authors have accepted responsibility for the entire content of this manuscript and approved its submission.

## References

1. Ghasemi M, Turnbull T, Sebastian S, Kempson I. The MTT assay: Utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis. *Int J Mol Sci.* 2021; 22(23):12827.
2. Potekhina ES, Bass DY, Kelmanson IV, Bessmertnykh-Vass YE, Skobeleva OI, Krylov AV. Drug screening with genetically encoded fluorescent sensors: today and tomorrow. *Int J Mol Sci.* 2021; 22(1):148.
3. Eroglu E, Gottschalk B, Charoensin S, Lim J, Smith JD, Lee M. Development of novel FP-based probes for live-cell imaging of nitric oxide dynamics. *Nat Commun.* 2016; 7(1):1–11.
4. Opelt M, Eroglu E, Waldeck-Weiermair M, De Jongh S, Toth L, Mukherjee S. Formation of nitric oxide by aldehyde dehydrogenase-2 is necessary and sufficient for vascular bioactivation of nitroglycerin. *J Biol Chem.* 2016; 291(46):24076–84.
5. Sevimli G, Alston AE, Funk F, Zhang M, Liao Y, Wang H. Probing subcellular iron availability with genetically encoded nitric oxide biosensors. *Biosensors.* 2022; 12(10):903.
6. Sevimli G, Smith MJ, Caglar TA, Chen Y, Liu Y, Li Z. Nitric oxide biosensor uncovers diminished ferrous iron-dependency of cultured cells adapted to physiological oxygen levels. *Redox Biol.* 2022; 53:102319.
7. Altun HY, Secilmis M, Yang F, Lu Y, Zhang X, Zhao H. Visualizing hydrogen peroxide and nitric oxide dynamics in endothelial cells using multispectral imaging under controlled oxygen conditions. *Free Radic Biol Med.* 2024; 221:89–97.



## Evaluation Of Plummer-Vinson Syndrome in Pediatric Patients with Dysphagia Disfaji Olan Çocuk Hastalarda Plummer-Vinson Sendromunun Değerlendirilmesi

SEVİNÇ GARİP <sup>1\*</sup>

<sup>1</sup> Sağlık Bilimleri Üniversitesi Adana Şehir Eğitim Uygulama ve Araştırma Hastanesi, Çocuk Sağlığı ve Hastalıkları Bölümü, Çocuk Gastroenteroloji Hepatoloji ve Beslenme Kliniği, Adana, Türkiye

Geliş Tarihi (Received): 05.09.2023

Kabul Tarihi (Accepted): 21.04.2024

Yayın Tarihi (Published): 29.08.2024

### Abstract

**Objective:** In our study, after excluding all other causes of dysphagia in the pediatric age, we tried to present the patients who were followed up and treated with the diagnosis of Plummer-Vinson syndrome (PWS) with iron deficiency anemia and dysphagia. Our aim is to emphasize that there may be dysphagia that can only be cured with anemia treatment and that it can be improved with treatment by a pediatrician.

**Materials and Methods:** Pediatric patients who applied to our hospital with the complaint of dysphagia between May 2019-November 2020 were included in the study. After excluding all other causes of dysphagia, patients diagnosed with PWS were evaluated retrospectively. It was aimed to evaluate the age, gender, type, characteristics and duration of dysphagia of the patients retrospectively and to present them in the light of the literature.

**Results:** PWS was detected in 24 of 200 pediatric patients who presented with dysphagia. The proportion of male patients was 37.5%, and their mean age was 97 months. The mean duration of dysphagia complaints was 11.2 months. Four patients had difficulty swallowing liquid food only, 12 patients had solid swallowing difficulties, and 8 patients had difficulty swallowing both solid and liquid food. Anemia was diagnosed by performing a complete blood count and having hemoglobin and hematocrit levels below 2 standard deviations appropriate for age; Those with vitamin B12 levels below 200 pg/ml were defined as cobalamin deficiency. Esophageal web was detected in 4 patients who underwent contrast esophagography. In esophagogastroduodenoscopy, stenosis was treated endoscopically in patients with web. In 20 patients, dysphagia did not persist after six months of iron deficiency anemia treatment.

**Conclusion:** Although the diagnosis of PVS is rare in children, it should be considered and treated in all children with dysphagia associated with iron deficiency anemia. Patients whose complaints continue after treatment at the appropriate dose and duration should be referred for pediatric gastroenterology evaluation.

**Keywords:** Child; Plummer-Vinson Syndrome; Iron-Deficiency Anemia; Esophageal Web, Dysphagia.

&

### Öz

**Amaç:** Disfaji çocukluk çağında sık görülmeye başlanmakta ve birçok nedene bağlı olarak gelişmektedir. Çalışmamızda pediatrik çağda disfajinin diğer tüm nedenleri dışlandıktan sonra demir eksikliği anemisi disfaji olan Plummer-Vinson sendromu tanısı ile takip ve tedavi edilen hastalar sunulmaya çalışılmıştır. Amacımız sadece anemi tedavisi ile düzelebilecek disfaji olabileceğini ve çocuk sağlığı ve hastalıkları uzmanı tarafından tedavi ile düzelebileceğini vurgulamaktır.

**Gereç ve Yöntemler:** Hastanemizde Mayıs 2019 ve Kasım 2020 arasında disfaji şikayeti ile başvuran, disfajinin diğer tüm nedenleri dışlandıktan sonra Plummer-Vinson sendromu tanısı alan hastalar retrospektif olarak değerlendirildi. Hastaların yaş, cinsiyet, disfaji şekli, özelliği ve süresi retrospektif olarak değerlendirilerek literatür eşliğinde sunmak amaçlanmıştır.

**Bulgular:** Disfaji şikayetiyle başvuran 200 çocuk hastanın 24'ünde PWS saptandı. Hastaların %37,5'u erkek olup, ortalama yaşları 97,5 aydı. Hastaların disfaji şikayet süresi ortalama 11,2 ay olup, 4 hastanın sadece sıvı gıda yutmada zorlanması varken 12 hastada katı, 8 hastada hem katı hem sıvıya karşı yutma güçlüğü mevcuttu. Tam kan sayımı yapılarak ve hemoglobin, hematokrit düzeyleri yaşa uygun 2 standart sapma değerinin altında olanlar anemi; vitamin B12 düzeyi 200 pg/ml değerinin altında olanlar kobalamin eksikliği olarak tanımlandı. Kontrastlı özofagografi çekilen 4 hastada özofageal web saptandı. Web saptanan hastaların özofagastroduodenoskopide darlık endoskopik olarak tedavi edildi. Yirmi hastada ise altı aylık demir eksikliği anemi tedavisi sonrası yutma güçlüğünün devam etmediği görüldü.

**Sonuç:** PVS tanısı çocuklarda nadir görülsede, demir eksikliği anemisi ile ilişkili yutma güçlüğü çeken tüm çocuklarda akla gelmeli ve tedavisi verilmelidir. Uygun dozda ve sürede tedavi sonrası şikayeti devam eden hastalar çocuk gastroenteroloji değerlendirmesi için yönlendirilmelidir.

**Anahtar Kelimeler:** Çocuk; Disfaji, Plummer-Vinson Sendromu; Özofageal Web; Demir Eksikliği Anemisi.

**Atıf/Cite as:** Garip S. Evaluation Of Plummer-Vinson Syndrome in Pediatric Patients with Dysphagia. Abant Med J. 13(2):45-51. doi:10.47493/abantmedj.1355176

\*Sorumlu Yazar (Corresponding Author): Sevinç Garip, e-mail: drsevincgarip@hotmail.com



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.



## Introduction

Swallowing is a complex situation that is possible with the coordinated work of many structures. Difficulty in swallowing is a symptom that occurs as a result of mechanical inhibition of the transfer of food from the mouth to the stomach, decreased strength of the muscles that provide the swallowing movement, or deterioration of coordination. Plummer-Vinson syndrome (PVS) is a tirade characterized by dysphagia, upper esophageal web, and iron deficiency anemia. There is no definitive data on its incidence and prevalence in the literature; only case reports have been published and it is very rare in childhood (1,2). The incidence of PVS has decreased due to the improvement of nutritional status with early detection and treatment of iron deficiency. Dysphagia is usually limited to solids and is intermittent or progressive over years. The esophageal webs are thin and transverse, extending into the esophageal lumen. They can be single or multiple. Esophageal web is not always necessary in patients with iron deficiency in PVS, but dysphagia is always necessary for diagnosis (3).

## Materials and Methods

In the study, 200 pediatric patients who applied to the Pediatric Gastroenterology outpatient clinic of Adana City Training and Research Hospital between May 2019 and November 2020 with the complaint of dysphagia were evaluated. The age, gender, type, characteristics and duration of dysphagia of the patients were evaluated. Hemogram, serum iron, iron binding capacity, ferritin were measured for iron deficiency anemia, and vitamin B12 level for concomitant vitamin B12 deficiency. Barium esophagography was performed to detect anatomical abnormalities. Non-web anatomical diseases were excluded from the study. May cause esophageal web; Other causes such as infectious citricides, corrosive burns, and heterotropic gastric mucosa were excluded from the study. To determine the cause of anemia, esophagogastroduodenoscopy was performed and biopsies were taken from the duodenum and stomach. Oral iron supplementation was given for at least 3 months to correct anemia and iron stores. All patients were instructed to follow up regularly after 3 months or if dysphagia recurred. All data were evaluated retrospectively in the light of the available literature. The study was approved by the scientific research ethics committee of our university. (approval date: 17.08.2023, meeting number:133, decision no:2772).

## Statistical Analysis

Parametric descriptive statistics of the numerical data in the study group were calculated as mean, standard deviation, and median (min-max) of non-parametric data, and categorical data were given as percent (%). The limit of significance was accepted as  $p < 0.05$ .

## Results

PWS was detected in 24 of 200 children who presented with dysphagia, after all other causes were excluded. In our study, the rate of male patients was 37.5% and female patient was 62.5%; their average age is 97 months; The mean duration of dysphagia complaint was 11 months. The shortest complaint period was 1 month and the longest 48 months. According to the dysphagia types, the patients were divided into three different groups including solid and liquid both types. Solid food group consisted of 12 cases, liquid food group consisted of 4 cases, and solid-liquid food group consisted of 8 cases. The characteristics of the patients according to the groups are shown in Table 1.


Complete blood count was performed, and those with hemoglobin and hematocrit levels below 2 standard deviations appropriate for age were accepted as anemia. Those with vitamin B12 levels below 200 pg/ml were defined as cobalamin deficiency. Vitamin B12 deficiency was accompanying in 3.5% of 24 patients with iron deficiency. Contrast esophagography was performed in 79% of 24 cases with PVS, and esophageal web was detected in 4 cases. Esophagogastroduodenoscopy was performed in 14 patients (58.3%) whose dysphagia was accompanied by anemia, for the diagnosis and treatment of webi, to exclude helicobacter pylori gastritis and pernicious anemia that may cause anemia. The web was shown by performing esophagogastroduodenoscopy in 4 patients with web. During the procedure, the stenosis was expanded endoscopically. There was slight bleeding due to the procedure, no other complications developed. Iron deficiency anemia treatment was started in the cases, and vitamin B12 treatment was started in the cases with vitamin B12 deficiency, and they were followed up for 6 months with 3-month intervals. After six months of

iron deficiency anemia treatment, the patients were excluded from follow-up, as it was observed that the dysphagia did not continue. PVS cases with web detected continued to be followed up with pediatric surgery.

**Table 1.**

Demographic And Clinical Features of Patients by Groups.

	Solid dysphagia	Liquid dysphagia	Solid and Liquid dysphagia
Gender	10 F/ 2M	2 F/ 2 M	2 F/ 6 E
Average age	119 month	45.5 month	115 month
Contrast esophagography	9 patient	3 patient	7 patient
Esophagogastroduodenoscopy	9 patient	3 patient	2 patient



**Figure 1.** Distribution of pediatric patients with Plummer-Vinson syndrome according to webs.

## Discussion

Plummer-Vinson syndrome (PVS) was first described by Henry Stanley Plummer in 1912 as upper esophageal spasms without anatomical stenosis. Surgeon Porter Paisley Vinso defined it in 1919 as dysphagia caused by esophageal stricture that can be treated surgically. In the United Kingdom; After Donal Ross Paterson described the esophageal web and dysphagia, Adam Brown-Kelly defined the classic triad of the syndrome. Therefore, this clinical syndrome is known as Plummer-Vinson syndrome in the USA and Paterson-Brown-Kelly syndrome in the UK (4). Plummer-Vinson syndrome (PVS) is a clinical condition characterized by dysphagia, upper esophageal web and iron deficiency anemia (5, 6). Webs, which are a rare cause of upper cervical dysphagia in children, are seen in 5-15% of patients with dysphagia (7). esophageal web; It is a thin

mucosal membrane localized just below the cricopharyngeal muscle, consisting of mucosa and submucosal tissue in the cervical esophagus, usually asymmetrically adherent to the anterior esophageal wall (8). Although most (89%) patients with inflammatory infiltrating PVS at biopsy were female in the adult literature (9). In our study, unlike the literature, female cases were more common than males (M: 37.5% F: 62.5%). The mean age of the cases was 97.5 months, and the mean duration of dysphagia complaints was 11 months. The shortest duration of the complaint was 1 month. There were also cases whose complaints lasted up to 48 months. Dysphagia in PVS is especially related to solid foods and in most cases it is painless, intermittent or progressive, but in some cases it can be progressive from solid food to liquid food (2, 10). In our study, the cases were divided into three different groups according to the dysphagia types as solid, liquid and both types. Contrast-enhanced radiographs could not be taken in 1 case in the liquid food dysphagia group, in 3 cases in the solid food dysphagia group, and in 1 case in both types of dysphagia group. When the groups were compared according to the results of esophagogastroduodenoscopy, no difference was observed. Esophagogastroduodenoscopy was not performed in 3 cases in the solid food dysphagia group, in 1 case in the liquid food dysphagia group, and 6 cases in the solid-liquid dysphagia group due to family preference. When the mean ages of the groups were compared, no statistically significant difference was found. Because the mean age of the solid and solid-liquid dysphagia groups was approximately the same. However, although the mean age in the liquid food dysphagia group was significantly younger than the other two groups, there was no statistically significant difference due to the small number of patients. Webs may be more than one, if the lumen diameter is narrower than 2 cm, dysphagia is observed, therefore most of them are asymptomatic (11). All the webs we detected in our study were odd in number and narrowed the esophageal lumen by approximately 80%. Accordingly, patients with web had difficulty in swallowing due to both solid and liquid food. In addition to dysphagia, weakness, fatigue, pallor, palpitation, glossitis, scoop nail, dyspepsia, weight loss, hoarseness, atrophic gastritis may accompany anemia. All of the cases in our study had normal body weight and height. However, other physical examination findings of the patients could not be accessed because they were not recorded in the computer system. This was the missing aspect of our study and shed light on future studies. The etiopathogenesis of PVS is unclear; Many genetic, environmental, nutritional, immunological and infectious causes are thought to play a role. The iron deficiency theory is based on the assumption that the decrease in iron-dependent oxidative enzymes gradually leads to atrophy and myopathy of the pharyngeal muscles and mucosa, resulting in the development of webs. Despite the persistence of webs after iron treatment, normalization of esophageal motility and improvement of dysphagia support the theory. However, it cannot explain why webs originating from squamous epithelium secondary to fibrosis due to submucosal inflammation are in the hypopharyngeal proximal esophagus.

Whatever the cause, iron deficiency causes rapid losses of iron-dependent enzymes due to high cell turnover. The reduction of these enzymes can lead to mucosal degenerations, atrophic changes and web formation, and even the development of cancer in the upper gastrointestinal tract (12). Studies have shown that iron deficiency leads to motility disorder by reducing the amplitude of contraction of the esophageal muscle (11, 13). In the study of Miranda and Dantas, the esophageal transit time of patients with iron deficiency anemia was slower in the proximal and middle parts of the esophagus than in normal healthy individuals, while no difference was found in the distal esophagus. This theory may explain why webs form in the proximal esophagus (14). Motility studies, especially manometry studies used to evaluate esophageal motility, are not easy to apply in children. For successful swallowing during monometry, it is necessary to be in harmony with the commands of the practitioner and a very good cooperation. It is very difficult to achieve this in childhood, especially in children younger than 7 years old. On the other hand, the number of experienced centers that can perform pediatric motility studies is insufficient. In our study, the rate of patients older than 7 years was 41.6% and motility studies were not performed in our center. Our study is important in terms of showing that there is a need for larger multicenter studies with a larger number of cases, including motility studies, with this missing aspect. Another proposed theory is that there is an immunological process that triggers the formation of autoantibodies against the esophagus (11). PVS; Some autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, pernicious anemia, thyroiditis or celiac disease should be investigated (15, 16, 17). It is unclear whether these autoimmune disorders cause PVS through autoantibody production or due to the inflammatory process and iron chelation (18). In our study, tauride tests and celiac antibodies, which were used to evaluate other diseases that may cause dysphagia, were found to be normal. Gastric biopsy samples taken during esophagogastroduodenoscopy were not compatible with pernicious

anemia. However, it was not evaluated because other specific findings of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's syndrome did not accompany the cases. The diagnosis is clinically made with dysphagia associated with chronic iron deficiency anemia, and esophageal webs are observed only in 10% of patients radiologically and endoscopically. Esophageal web is not always necessary in patients with iron deficiency in PVS, but dysphagia is always necessary for diagnosis (3).

Contrast-enhanced radiographs are important in the diagnosis of PWS, especially in showing webs on lateral images (19, 20). In severe cases, a ring-shaped stenosis may occur even if barium esophagography is normal. In 1975 Noshier JL. et al. In his study, when the proximal esophagus was evaluated in 1000 radiographs, 1 or more webs were found in 5.5% of the esophagus (21). In the 1974 study of Chisholm M. et al. only 10% of patients with iron deficiency anemia reported esophageal mesh. In our study, web was detected in 17% of 24 PVS cases, which is similar to the literature. However, web was detected in only 2% of 200 children who presented with dysphagia. Barium radiographs, especially upper esophageal anomalies, are difficult to evaluate. Because studies on swallowing in childhood are difficult due to coordination problems. However, the number of experienced teams to evaluate barium radiographs during serial shooting is insufficient. We think that the rate of web detection will increase when appropriate conditions are met.

Webs can also be detected by upper endoscopy. Upper esophageal webs can be easily overlooked in endoscopic examination, and there is a risk of perforation. Iron deficiency anemia was found in 38.5% of 135 patients with web detected by esophagogastroduodenoscopy, and low serum ferritin levels were found in 0.7% without anemia (22). Our study was similar to that of Godino et al. In our study, esophagogastroduodenoscopy was performed in 58.3% of the cases. In 4 of 14 patients who underwent esophagogastroduodenoscopy, the web, which was also detected in contrast-enhanced radiography, was shown and treated. Treatment options include iron supplementation, esophageal dilation, or both. Iron therapy should be continued until hematocrit and ferritin levels return to normal. This treatment provides significant improvement in dysphagia in patients who are not completely obstructive. Clinical studies have shown that iron intake also improves esophageal motility in these patients. However, patients with severe and prolonged dysphagia do not respond to iron support and generally require mechanical dilation of the stenosis, and surgical treatment is very rarely required (23, 24, 25). In pediatric patients, 93% of PVS patients require an upper endoscopy and 64% require endoscopic expansion. It shows that the response to iron treatment is lower than adults. In many cases, unlike adults, a single dilatation procedure is sufficient (26). In a three-year study of 37 patients with PVS, 94% of symptomatic patients showed resolution of dysphagia after 1 endoscopic dilatation. 10% recurrence was observed in the ten-month follow-up (27). In another study, 1 session of Savary-Gilliard bougie dilatation was performed in 153 patients, 132 of whom had PVS, and it was observed that dysphagia did not continue in 90.7% of the patients (28). In our study, 3% iron deficiency anemia, 6.5% vitamin B12 deficiency, 6% iron deficiency and vitamin B12 deficiency were found in 200 pediatric patients with dysphagia. A single session of endoscopic dilatation was performed together with iron treatment in 4 patients in whom we detected web, and only slight bleeding was observed. Other PVS cases without web did not complain of dysphagia after 3-6 months of iron deficiency treatment.

In conclusion; Dysphagia started to be seen frequently in childhood and develops due to many reasons. The diagnosis of PVS is rare in children, but it should be considered in all children with dysphagia associated with iron deficiency anemia. Patients with dysphagia, whose complaints persist despite 6 months of treatment, should be referred to pediatric gastroenterology.

**Ethics Committee Approval:** The study was approved by the Adana City Training And Research Hospital Clinical Research Ethics Committee (date: 17.08.2023 and approval number: 133/2772).

**Informed Consent:** Written consent was obtained from the participants.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors declared no financial support.

**Acknowledgement:** We would like to thank the Pediatric Health and Diseases Clinic staff who contributed to the diagnosis and treatment processes of the patients who participated in the relevant study.

**Author Contributions:** Idea/Concept: S.G.; Design: S.G.; Supervision: S.G.; Funding: S.G.; Materials: S.G.; Data Collection/Processing: S.G.; Analysis/Interpretation: S.G.; Literature Review: S.G.; Drafting/Writing: S.G.; Critical Review: S.G. The authors have accepted responsibility for the entire content of this manuscript and approved its submission.

## References

1. Crawford MD, Jacobs A, Murphy B, Peters DK. Paterson-Kelly syndrome in adolescence: a report of five cases. *Br Med J.* 1965;1: 693-695.
2. Seitz ML, Sabatino D. Plummer-Vinson syndrome in an adolescent. *J Adolesc Health* 1991;12: 279-281.
3. Wynder EL, Fryer JH. Etiologic considerations of Plummer-Vinson (Patterson-Kelly) syndrome. *Ann Intern Med.* 1958;49:1106-28.
4. Kelly AB. Spasm at the entrance of the esophagus. *J Laryngol Rhinol Otol.* 1919;34:285-89.
5. Plummer S. Diffuse dilatation of the esophagus without anatomic stenosis (cardiospasm). A report of ninety one cases. *J Am Med Assoc.* 1912;58: 2013-2015.
6. Paterson DR. Clinical type of dysphagia. *J Laryngol Rhinol Otol* 1919; 24: 289-291.
7. Godino J, Wong PW. A triad of troubling findings. Plummer-Vinson syndrome. *Postgrad Med* 2000;108:109-10.
8. Hoffman RM, Jaffe PE. Plummer-Vinson syndrome. A case report and literature review. *Arch Intern Med* 1995;155:2008-11.
9. Novacek G. Plummer-Vinson syndrome. *Orphanet J Rare Dis* 2006; 1:36.
10. Daghfous MH, Slim R, Mouelhi M, L Hendeou. Esophageal transit in the Plummer-Vinson syndrome. *Ann Radiol (Paris).* 1985;28:533-9.
11. Dantas RO, Villanova MG. Esophageal motility impairment Plummer-Vinson syndrome. Correction by iron treatment. *Dig Dis Sci.* 1993;38:968-71.
12. Anderson SR, Sinacori JT. Plummer-Vinson syndrome heralded by postcricoid carcinoma. *Am J Otolaryngol.* 2007; 28: 22-24.
13. Dantas RO. Iron deficiency and dysphagia. *Am J Gastroenterol.* 1999; 94: 3072-3073.
14. Miranda AL, Dantas RO. Esophageal contractions and oropharyngeal and esophageal transits in patients with iron deficiency anemia. *Am J Gastroenterol.* 2003; 98: 1000-1004.
15. Makharia GK, Nandi B, Garg PK, Tandon RK. Plummer-Vinson syndrome: unusual features. *Indian J Gastroenterol.* 2002;21:74-5.
16. Malhotra P, Kochhar R, Varma N, S Kumari, S Jain, S Varma. Paterson-Kelly syndrome and celiac disease- a rare combination. *Indian J Gastroenterol.* 2000;19:191-2.
17. Dickey W, McConnell B. Celiac disease presenting as the PatersonBrown Kelly (Plummer-Vinson) syndrome. *Am J Gastroenterol* 1999;94:527-9.
18. Butori M, Mahmoudi S, Dugelay Ecohard E, et al. *J Pediatr Gastroenterol Nutr* 2015;61(5):547-52.
19. Hoffman RM, Jaffe PE. Plummer-Vinson syndrome. A case report and literature review. *Arch Intern Med.* 1995;155:2008-11.
20. Enomoto M, Kohmoto M, Arafa UA et al. Plummer-Vinson syndrome successfully treated by endoscopic dilatation. *J Gastroenterol Hepatol.* 2007;22:2348-51.
21. Noshier JL, Campbell WL, Seaman WB. The clinical significance of cervical esophageal and hypopharyngeal webs. *Radiology* 1975;117(1):45-47.
22. Chisholm M. The association between webs, iron and post-cricoid carcinoma. *Postgrad Med J* 1974;50(582):215-19.
23. Beyler AR, Yurdaydin C, Bahar K, Gören A, Soykan I, Uzunalimoğlu O. Dilation therapy of upper esophageal webs in two cases of Plummer-Vinson syndrome. *Endoscopy* 1996;28:266-7.
24. Demirci F, Savaş MC, Kepkep N et al. Plummer-Vinson syndrome and dilation therapy: a report of two cases. *Turk J Gastroenterol* 2005;16:224-7.
25. Ribeiro U Jr, Posner MC, Safatle-Ribeiro AV, Reynolds JC. Risk factors for squamous cell carcinoma of the oesophagus. *Br J Surg* 1996;83:1174-85.
26. Katsinelos P, Gkagkalis S, Chatzimavroudis G, Zavos C, Spyridakis J, Kountouras J. Recurrent esophageal web in Plummer-Vinson syndrome successfully treated with postdilation intralesional injection of mitomycin C. *Gastrointest Endosc.* 2012;75:1124.



27. Goel A, Lakshmi CP, Bakshi SS, Soni N, Koshy S. Single-center prospective study of Plummer-Vinson syndrome. *Dis Esophagus*. 2016;29(7):837-41.
28. Patil M, Malipatel R, Devarbhavi H. Plummer-Vinson syndrome: A decade's experience of 132 cases from a single center. *J Gastroenterol Hepatol*. 2021;36(1):181-85.
29. Lopez Rodriguez MJ, Robledo Andres P, Amarilla Jimenez A, Roncero Maillo M, Lopez Lafuente A, Arroyo Carrera I. Sideropenic dysphagia in an adolescent. *J Pediatr Gastroenterol Nutr*. 2002; 34: 87-90.





## Retrospective Comparison of Talon or Conventional Locking Nailing for Tibial Shaft Fractures

Tibia Gövde Kırıklarında Talon ve Geleneksel Kilitli Çivilemenin Retrospektif Karşılaştırması

Fatih GÜNAYDIN<sup>1</sup> , Öner KILINÇ<sup>1</sup> , Bülent SAKARYA<sup>1</sup> , Yusuf BAYRAM<sup>2\*</sup>

<sup>1</sup>Mersin Training and Research State Hospital, Mersin, Türkiye

<sup>2</sup>Hisar Intercontinental Hospital, İstanbul, Türkiye

Geliş Tarihi (Received): 06.12.2023

Kabul Tarihi (Accepted): 23.07.2024

Yayın Tarihi (Published): 29.08.2024

### Abstract

**Objective:** Tibial shaft fractures are common orthopedic injuries that present challenges in treatment selection. The primary aim of this retrospective study was to compare the clinical outcomes of tibial shaft fractures treated with Talon and conventional locking nails.

**Materials and Methods:** Ninety-four patients who underwent tibial intramedullary nailing between 2019 and 2021 were included in the study. The patients were divided into two groups based on the type of distal locking used: Group 1 received conventional screw locking, and Group 2 received Talon locking. Patient age, gender, trauma mechanism, fracture type, and surgery data were analyzed. The complications and bone union processes during follow-up were evaluated and compared between the two nail designs.

**Results:** The age and gender of the patients included in the study were statistically similar in both groups. Furthermore, the Talon group demonstrated significantly shorter union times ( $p < 0.001$ ). According to the OTA classification, there was a preference for screw-locking systems in more complex fractures ( $p = 0.017$ ).

**Conclusion:** The results of this retrospective study suggest that Talon locking nails may offer advantages over conventional screw locking, especially in younger patients, resulting in earlier bone union. Further research is needed to investigate Talon nails' biomechanical stability and suitability for specific fracture types.

**Keywords:** Tibial Shaft Fractures, Locking Nails, Talon Nail, Conventional Locking Nail.

&

### Öz

**Amaç:** Tibia gövde kırıkları, ortopedik tedavilerde yaygın ve zorlayıcı yaralanmalardır. Bu retrospektif çalışma, Talon ve geleneksel vida kilitleme çivileriyle tedavi edilen hastaların klinik sonuçlarını karşılaştırmayı hedeflemektedir.

**Gereç ve Yöntemler:** 2019-2021 yılları arasında tibia shaft kırığı nedeniyle intramedüller çivi operasyonu geçiren 94 hasta bu çalışmaya dâhil edildi. Hastalar, uygulanan distal kilitleme yöntemine göre iki gruba ayrıldı: Birinci grup geleneksel vida, ikinci grup ise Talon kilitleme yöntemi ile ameliyat edilen hastalar olarak belirlendi. Hastaların yaş, cinsiyet, travma mekanizması, kırık tipi ve cerrahi bilgileri incelendi. İyileşme sürecindeki komplikasyonlar ve kemik birleşme durumları her iki çivi tasarımı için değerlendirildi.

**Bulgular:** Çalışmaya alınan hastaların yaş ve cinsiyetleri her iki grupta da istatistiksel olarak benzerdi. Talon grubunda anlamlı derecede daha kısa kaynama süresi gözlemlendi ( $p < 0.001$ ). OTA sınıflandırmasına göre daha karmaşık kırıklarda vida kilitleme sistemlerinin daha sık tercih edildiği gözlemlendi ( $p=0.017$ ).

**Sonuç:** Özellikle genç hastalarda, Talon kilitleme çivilerinin geleneksel vida kilitlemeye göre bazı avantajlar sunduğu ve daha hızlı kırık kaynamasına katkıda bulunduğu gözlemlenmiştir. Talon çivilerinin biyomekanik stabilitesi ve özel kırık tiplerine uygunluğu üzerine daha fazla araştırma yapılması önerilmektedir.

**Anahtar Kelimeler:** Tibia Shaft Kırığı, Kilitli Çivi, Talon Çivi, Geleneksel Kilitli Çivi.

**Atıf/Cite as:** Günaydın F, Kılınç Ö, Skaraya B, Bayram Y. Retrospective Comparison Of Talon Or Conventional Locking Nailing For Tibial Shaft Fractures. Abant Med J. 13(2):52-58. doi:10.47493/abantmedj.1373188

\*Sorumlu Yazar (Corresponding Author): Yusuf Bayram, e-mail: dryusuf34@gmail.com



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

## Introduction

Tibial shaft fractures are common injuries that pose significant challenges in orthopedic practice. The choice of fixation method plays a crucial role in achieving optimal outcomes for these fractures. In recent years, there has been growing interest in locking nails for tibial shaft fractures due to their biomechanical advantages and potential clinical benefits. The conventional locking nail technique has been widely utilized to treat tibial shaft fractures (1, 2). This technique involves using a non-locking nail with interlocking screws placed proximally and distally to provide stability. While this method has shown satisfactory outcomes in many cases, concerns have been raised regarding the risk of screw backout, rotational instability, and delayed fracture healing(3). The Talon nail, a newer generation locking nail system, has been introduced in response to these concerns. Despite the growing popularity of the Talon nail, limited comparative studies have been conducted to evaluate its efficacy and compare it with conventional locking nails. Therefore, this retrospective study aims to fill this knowledge gap by retrospectively comparing the clinical outcomes of tibial shaft fractures treated with either the Talon nail or conventional locking nails.

## Materials and Methods

This study was conducted in accordance with the Declaration of Helsinki and received approval from the Ethics Committee on May 8, 2023 (approval no: 215040260). We retrospectively analyzed 94 patients (81 males and 13 females) who underwent tibial intramedullary nailing for tibial shaft fractures between 2019 and 2021. The study included patients aged 18 and older who required surgical intervention with an intramedullary nail for tibial shaft fractures. Exclusion criteria were previous fractures at the same site, segmental tibial fractures, metabolic bone diseases, or prior surgeries on the affected limb.

The minimum follow-up period was 12 months, allowing for adequate assessment of post-surgical outcomes and long-term bone union. Surgeries were carried out by multiple surgeons with comparable levels of expertise, all adhering to the center's standardized surgical protocols to minimize variability in the outcomes. Patients were divided into two groups based on the distal locking method used: Group 1 received conventional screw locking, while Group 2 underwent Talon-locking.

Data on participants' age, gender, trauma mechanism, fracture type, and surgical details were collected. We also monitored complications and the bone union process during follow-up. Statistical analyses were performed using SPSS for Windows 25.0 (Armonk, NY: IBM Corp.). We used the Kolmogorov-Smirnov/Shapiro-Wilk tests to assess the normality of continuous variable distributions, with p-values above 0.05 indicating normal distribution. Descriptive statistics were presented as means, standard deviations, medians with ranges for quantitative variables, and frequencies and percentages for qualitative variables. The Mann-Whitney U test was utilized for quantitative comparisons and the chi-square test for qualitative data, with a significance threshold set at  $p < 0.05$ . Radiological images of tibial shaft fractures treated with conventional and Talon-locking nails were reviewed to support the comparative analysis (Figure 1).


## Results

A total of 94 patients were analyzed. Group 1 included 56 male patients, while Group 2 included 25 male patients. The average age was 34 years in Group 1 and 32 years in Group 2. There was no statistically significant difference in smoking habits between the groups.

The distribution of trauma mechanisms was similar between the groups, with falls from height, motorcycle accidents, and non-vehicular traffic accidents being equally represented. The incidence of open fractures was 30.3% in Group 1 and 20% in Group 2 ( $p=0.368$ ).

Reduction types varied significantly between the groups. All patients in Group 2 underwent closed reductions, while in Group 1, 60.6% of patients underwent open reductions ( $p < 0.001$ ).

Alignment outcomes showed normal alignment in 87.9% of patients in Group 1 and 100% in Group 2 ( $p=0.108$ ). Complications were observed in Group 1, including screw breakage (6.1%) and pseudoarthrosis (3%), while no complications were reported in Group 2 ( $p=0.376$ ).



A) AP radiograph of the patient with conventional screw locking, B) Lateral radiograph of the patient with conventional screw locking, C) AP radiograph of the patient with talon distal locking, D) Lateral radiograph of the patient with talon distal locking

**Figure 1.** Patient X-rays operated with Talon and conventional locking nails

Healing times indicated a faster recovery for Group 2, with 70% achieving bone union by 3 months, compared to 18.2% in Group 1 within the same timeframe ( $p < 0.001$ ).

The AO classification showed different preferences for the treatment methods, with the screw-locking system being used more frequently for managing more complex fractures.

A retrospective analysis was conducted on 94 patients. In Group 1, there were 56 male patients, while Group 2 consisted of 25 male patients, indicating a predominance of male gender in both groups. The average age was 34 years in Group 1 and 32 years in Group 2, with similar age distributions across the groups. No statistically significant difference was found in smoking habits between the groups. The mechanisms of

trauma, including falls from height, motorcycle accidents, and non-vehicular traffic accidents, were similarly distributed between the groups. Table 1 summarizes the general characteristics of the patients.

**Table 1**

General Characteristics of Patients

	Locking Screw	Talon	p-value
Age, Median (min-max)	34 (17-58)	32 (18-58)	0.345
Gender, n (%)			0.417
Female	10 (15.2%)	3 (10.7%)	
Male	56 (84.8%)	25 (89.3%)	
Smoking habits, n (%)			0.258
No	22 (33.3%)	12 (42.9%)	
Yes	44 (66.7%)	16 (57.1%)	
Trauma type, n (%)			0.703
Fall down	22 (33.3%)	9 (32.1%)	
Motorcycle accident	22 (33.3%)	8 (28.6%)	
Pedestrian vehicle accident	22 (33.3%)	11 (39.3%)	

n: Number of Individuals. For statistical comparison, The chi-square test was used

The incidence of open fractures did not significantly differ between the groups, with 30.3% in Group 1 and 20% in Group 2 ( $p=0.368$ ). Reduction type varied significantly; all patients in Group 2 underwent closed reductions, in contrast to Group 1, where 60.6% underwent open reductions ( $p<0.001$ ).

Regarding alignment and complications, both groups reported high rates of normal alignment, 87.9% in Group 1 and 100% in Group 2, though this difference was not statistically significant ( $p=0.108$ ). Group 1 experienced some complications, such as screw breakage (6.1%) and pseudoarthrosis (3%), whereas Group 2 reported no complications, but these differences were not statistically significant ( $p=0.376$ ). Additional pathologies and trauma causes were similar across groups, with no significant differences observed in the presence of additional injuries or the causes of trauma.

Healing times indicated a faster recovery for Group 2, with 70% achieving bone union by 3 months, compared to 18.2% in Group 1 within the same timeframe ( $p<0.001$ ).

The AO classification showed different preferences for the treatment methods, with the screw-locking system being used more frequently for managing more complex fractures.

Table 2 shows the comparison of the fractures and the findings between the groups after treatment.

**Table 2**

Comparative Analysis of Fracture Types and Treatment Outcomes Between Groups

	Locking Screw	Talon	p-value
OTA Classification (n%)			0.017
42a	26 (39.4%)	20 (71.4%)	
42b	28 (42.4%)	5 (17.9%)	
42c	12 (18.2%)	3 (10.7%)	
Trauma type (n%)			0.703
Fall down	22 (33.3%)	9 (32.1%)	
Motorcycle accident	22 (33.3%)	8 (28.6%)	
Pedestrian vehicle accident	22 (33.3%)	11 (39.3%)	
Open Fracture (n%)			0.269
No	46 (69.7%)	22 (78.6%)	
Yes	20 (30.3%)	6 (21.4%)	
Union time (months)			< 0.001*
Median (min-max)	5 (2-11)	3 (3-5)	
Alignment (n%)			
Normal	58 (87.9%)	28 (100%)	0.052
Valgus	8 (12.1%)	-	
Varus	-	-	
Other Trauma (n%)			
None			
2 Fracture	46 (69.7%)	17 (60.7%)	
3 Fracture	14 (21.2%)	6 (21.4%)	0.257
Head Trauma	2 (3%)	2 (7.1%)	
	4 (6.1%)	3 (10.7%)	

n: Number of Individuals. For statistical comparison, The chi-square test and \*Mann-Whitney U test were used

## Discussion

The patients who participated in our study were similar in age, gender, smoking, and fracture type, which may be related to fracture union. Additionally, our study corroborates previous literature, showing male dominance in both the Screw and Talon groups (4-6).

The most intriguing finding of our study is the significantly earlier union time observed in the Talon group. While the younger age of our study population may contribute to an expectation of earlier union regardless of the treatment type, it is noteworthy that this result contradicts some published data. For instance, Tekin et al. (4) reported earlier union in the Screw locking group compared to the Talon locking group. Similarly, Yalkın et al. (5) found longer union times in the Talon group. A study on Talon and conventional screw-locking nails in femur fractures also reported longer union time in the Talon group (6). However, with its younger patient population, our study demonstrated a shorter union time in the Talon group compared to conventional screw locking, which the age factor could explain.

Moreover, according to the OTA classification, we observed a preference for screw-locking systems in more complex fractures. In our study, eight patients in the screw-locking system group exhibited valgus malalignment, while no malalignment was observed in any patient in the Talon group. This discrepancy is likely due to the variation in fracture classes between the two groups.

Limitations of the study:

- Retrospective design
- Lack of randomization
- Single-center study
- Heterogeneity of fractures
- Limited follow-up duration
- Lack of biomechanical data
- Lack of control group

## Conclusion

In the surgical treatment of tibial shaft fractures, intramedullary nails equipped with Talon distal locking have demonstrated advantages over conventional screw locking nails, including shorter healing times and lower complication rates. Further biomechanical studies and randomized prospective trials are essential to deepen our understanding of these outcomes. Such research will provide more definitive evidence on the efficacy of Talon locking systems, potentially leading to optimized treatment protocols for these common injuries.

**Ethics Committee Approval:** The study was approved by the Declaration of Helsinki. Approval was granted by the Ethics Committee (date: 08.05.2023 and approval number: 215040260).

**Informed Consent:** Written consent was obtained from the participants.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors declared no financial support.

**Author Contributions:** Idea/Concept: F.G., Ö.K., B.S., Y.B.; Design: F.G., Ö.K., B.S., Y.B.; Supervision: F.G., Ö.K., B.S., Y.B.; Funding: F.G., Ö.K., B.S., Y.B.; Materials: F.G., Ö.K., B.S., Y.B.; Data Collection/Processing: F.G., Ö.K., B.S., Y.B.; Analysis/Interpretation: F.G., Ö.K., B.S., Y.B.; Literature Review: F.G., Ö.K., B.S., Y.B.; Drafting/Writing: F.G.; Critical Review: F.G., Ö.K., B.S., Y.B. The authors have accepted responsibility for the entire content of this manuscript and approved its submission.

## References

1. Donnelley CA, von Kaeppler EP, Roberts HJ, Haonga B, Shearer DW, Morshed S. Monoplanar external fixation of comminuted open tibial shaft fractures predicts loss of alignment by one year compared to a



- statically locked intramedullary SIGN nail. *Injury*. 2021;52(4):982-7. Epub 2020/11/10. doi: 10.1016/j.injury.2020.10.078. PubMed PMID: 33164834.
2. ÜZÜMCÜGİL O, DOĞAN A, YALÇINKAYA M, DAĞTAŞ MZ, AZAR N, MUMCUOĞLU E, et al. Tibia diyafiz kırıklarının kilitli intramedüller çivileme ile tedavisinde orta dönem sonuçlarımız. *Şişli Etfal Hastanesi Tıp Bülteni*. 2009;43(2):82-8.
  3. Bhandari M, Guyatt GH, Swiontkowski MF, Tornetta P, 3rd, Sprague S, Schemitsch EH. A lack of consensus in the assessment of fracture healing among orthopaedic surgeons. *J Orthop Trauma*. 2002;16(8):562-6. Epub 2002/09/28. doi: 10.1097/00005131-200209000-00004. PubMed PMID: 12352564.
  4. Tekin SB, Mert A, Bozgeyik B. Which is superior in the treatment of AO Type 42A tibial shaft fracture? A comparison of talon intramedullary nailing and conventional locked intramedullary nailing. *Ulus Travma Acil Cerrahi Derg*. 2022;28(10):1514-20. Epub 2022/09/29. doi: 10.14744/tjtes.2021.36779. PubMed PMID: 36169461; PubMed Central PMCID: PMC10277372.
  5. Çamurcu Y, Sofu H, Issin A, Koçkara N, Genç E, Çetinkaya M. Is talon tibial intramedullary nailing clinically superior compared to conventional locked nailing? *Eklemler Hastalıkları Cerrahisi*. 2017;28(3):152-7. Epub 2017/11/11. doi: 10.5606/ehc.2017.55349. PubMed PMID: 29125812.
  6. Yapıcı F, Gür V, Onaç O, Alpay Y, Tardus I, Üçpunar H, et al. For Intramedullary Nailing of Femoral Shaft Fractures, Talon Fixation is Helpful to Cope With the Troublesome Distal Locking, But Conventional Distal Locking With Screws Offers a More Stable Construct. *Talon Femoral Nail Versus Conventional Femoral Nail*. *Ulus Travma Acil Cerrahi Derg*. 2022;28(4):513-22. Epub 2022/04/30. doi: 10.14744/tjtes.2021.55867. PubMed PMID: 35485511.



## COVID-19 Pneumonia-Related ARDS – Can We Predict Mortality with Laboratory Parameters?

### COVID 19 Pnömonisi Sonrası Gelişen ARDS'de Laboratuvar Parametreleri Mortaliteyi Öngörmeye Kullanılabilir Mi?

Emine ÖZSARI<sup>1\*</sup> , Muhammed Emin DEMİRKOL<sup>2</sup> , Süleyman ÖZSARI<sup>3</sup> 

Musa KAYA<sup>4</sup> , Derya KOCADAĞ<sup>5</sup> , Zeynep BAYSAL<sup>5</sup> 

<sup>1</sup> Bolu Abant İzzet Baysal University Hospital, Department of Pulmonary Medicine, Bolu, Türkiye

<sup>2</sup> Bolu Abant İzzet Baysal University Faculty of Medicine, Department of Internal Medicine, Türkiye

<sup>3</sup> Bolu Abant İzzet Baysal University Faculty of Medicine, Department of Family Medicine, Bolu, Türkiye

<sup>4</sup> Zonguldak Atatürk State Hospital, Department of Emergency Medicine, Zonguldak, Türkiye

<sup>5</sup> Bolu Provincial Health Directorate, Bolu, Türkiye

Geliş Tarihi (Received): 17.01.2024 Kabul Tarihi (Accepted): 18.07.2024 Yayın Tarihi (Published): 29.08.2024

#### Abstract

**Objective:** To examine the laboratory characteristics of COVID-19 pneumonia-related ARDS patients who lived or died.

**Materials and Methods:** Retrospectively, two-center of patients who were hospitalized in the intensive care unit were researched in Abant İzzet Baysal University Education and Research Hospital in Bolu, Turkey. Between March 31 and December 31, 2020, data on the demographic characteristics, routine laboratory results, including arterial blood gas tests, and clinical outcomes were collected for both the survivor and non-survivor groups.

**Results:** The median age of the 509 patients was 70 years (interquartile range, 59-79 years); 326 patients (64%) were men, and 161 patients (31.6%) tested positive for RT-PCR. While 232 (45.6%) patients in the non-survivor group died, 277 patients were discharged (54.4%) as survivors. The mortality markers of WBC, RBC, HGB, Ph, pO<sub>2</sub>, pCO<sub>2</sub>, HCO<sub>3</sub>, PLT, PCT, NEU, ALT, and D-dimer did not differ significantly (p>0.05). CRP, RDW, LDH, ferritin, urea, and creatinine levels were substantially higher and associated with death in the non-survivor group (p 0.05).

**Conclusion:** A greater risk of death was linked to older age and the number of days spent in the hospital, most likely as a result of persistent underlying issues and weakened immune responses. Risk variables for the progression were CRP, LDH, RDW, ferritin, urea, and creatinine. With the help of laboratory parameters to predict mortality, we can define earlier the changes in immune insufficiency, coagulation problems, hepatic injury, and kidney injury.

**Keywords:** ARDS, COVID 19, Laboratory Parameters, Mortality.

&

#### Öz

**Amaç:** Yaşayan veya ölen COVID-19 pnömonisine bağlı ARDS hastalarının laboratuvar özelliklerini incelemek.

**Gereç ve Yöntemler:** Bolu Abant İzzet Baysal Üniversitesi Eğitim ve Araştırma Hastanesi'nde yoğun bakım ünitesinde yatan hastaların iki merkezi retrospektif olarak araştırıldı. 31 Mart ile 31 Aralık 2020 tarihleri arasında hem hayatta kalan hem de hayatta kalmayan gruplar için demografik özellikler, arteriyel kan gazı testleri dahil rutin laboratuvar sonuçları ve klinik sonuçlara ilişkin veriler toplandı.

**Bulgular:** 509 hastanın ortanca yaşı 70 (çeyrekler arası aralık, 59-79 yıl) idi; 326 hasta (%64) erkekti ve 161 hastanın (%31,6) RT-PCR testi pozitif çıktı. Hayatta kalan grupta 232 (%45,6) hasta hayatını kaybederken, 277 hasta (%54,4) sağ olarak taburcu edildi. WBC, RBC, HGB, Ph, pO<sub>2</sub>, pCO<sub>2</sub>, HCO<sub>3</sub>, PLT, PCT, NEU, ALT ve D-dimer mortalite belirteçleri anlamlı farklılık göstermedi (p>0,05). Hayatta kalmayan grupta CRP, RDW, LDH, ferritin, üre ve kreatinin düzeyleri önemli ölçüde daha yüksekti ve ölümlle ilişkiliydi (p < 0.05).

**Sonuç:** Daha büyük ölüm riski, ileri yaş ve hastanede geçirilen gün sayısı ile bağlantılıydı; büyük ihtimalle kalıcı altta yatan sorunlar ve zayıflamış bağışıklık tepkilerinin bir sonucuydu. İlerlemeye ilişkin risk değişkenleri CRP, LDH, RDW, ferritin, üre ve kreatinindi. Mortaliteyi tahmin etmeye yönelik laboratuvar parametrelerinin yardımıyla bağışıklık yetersizliği, pıhtılaşma sorunları, karaciğer hasarı ve böbrek hasarındaki değişiklikleri daha erken tanımlayabiliriz.

**Anahtar Kelimeler:** ARDS, COVID 19, Laboratuvar Parametreleri, Mortalite.

**Atıf/Cite as:** Özsarı E, Demirkol ME, Özarsarı S, Kaya M, Kocadağ D, Baysal Z. COVID-19 Pneumonia-Related ARDS – Can We Predict Mortality with Laboratory Parameters?. Abant Med J. 13(2):59-66. doi:10.47493/abantmedj.1416495

\*Sorumlu Yazar (Corresponding Author): Emine Özsarı, e-mail: dreminedemirok@hotmail.com



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

## Introduction

Since the outbreak of Coronavirus disease 2019 (COVID- 19), the approach of severe and critical patients has remained a clinical challenge. Despite of the respiratory support, antiviral drugs and immunomodulators, it's still likely to develop Severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV2) was first reported in China and has spread to Turkey since March 2020. There have been 636 million instances reported globally as of October 31, 2022, with 6,6 million fatalities (1). Data from the Turkish Ministry of Health show that as of the publication date (October 31, 2022), 17 million confirmed cases have been detected in Turkey, with a case-fatality rate of 1% (2). Case (ARDS) for the patients and eventually invasive ventilation.

The mortality rates of cases range from 1.7 to 2.23 percent globally (3). The belong to the geographic location, the virus's rate of transmission, and the proportion of the population at risk all influence the prevalence and mortality rates risks (3). In addition, some factors that affected these criteria were the health system's readiness, the availability of hospitals, and the number of beds in intensive care units (ICUs) (4). The apparent variations in fatality rates These results might also be due to variances in the categorization and reporting of COVID-19 cases and related fatalities. The WHO dashboard presently only includes real-time polymerase chain reaction (RT-PCR)- --positive cases, which might cause the actual situation to be underestimated (1). A high proportion of PCR-negative people with clinical and radiographic traits consistent with COVID-19 are identified and handled as such in clinical practice (5). Furthermore, rates of false negative PCR tests are anticipated to vary between 2 and 29 percent (6).

Numerous investigations have demonstrated that COVID-19 pneumonia has had certain specific epidemiological and clinical features in the past (7,8). However, the risk factors for poor clinical outcomes have not yet been found, particularly in COVID-19 pneumonia-related acute respiratory distress syndrome (ARDS).. Even though several papers researchs have shown death rates and risk factors globally, we still don't have much information on the characteristics of proven or strongly suspected cases in Turkey, specifically forecasting fatality. In this research, the laboratory features of the pneumonia-related ARDS in COVID-19 to death from two tertiary ICU units in Bolu, Turkey, are presented. We sought to explain the demographic and laboratory factors that distinguished critically sick individuals patients who would survive from those who wouldn't, as these factors were crucial in predicting death.

## Materials and Methods

### Study Design

This multicenter registry study was approved by the Institutional Review Board (IRB) of the University Faculty of Abant İzzet Baysal University Faculty of Medicine (2020/327). The clinical outcomes of patients were evaluated retrospectively from data hospitalized in tertiary ICU at Abant İzzet Baysal University Hospital and İzzet Baysal State Hospital in Bolu, Turkey. No informed consent was required, because of the retrospective design of the study. All patients were managed according to the guidelines of the Ministry of Health of Turkey (2). The demographic features, routine laboratory findings including arterial blood gas analyses, and clinical outcomes were recorded between March 31 and December 31, 2020.

### Case Definition

The WHO COVID-19 case definition sheet was used to include the patients in the study. As a result, a confirmed case was defined as the presence of a positive nucleic acid amplification test or a positive fast antigen detection test, as well as clinical and radiographic features strongly suggesting COVID-19 (9). Despite matching clinical and radiographic signs in very likely occurrences, an RT-PCR assay was unable to confirm (9). The final diagnosis was made using the following criteria (9–11).

### Procedures

Patients received a variety of Numerous procedures, including were administered to the patients, such as coagulation, hemograms, ferritin, C-reactive protein (CRP), D-dimer assays, hemograms, coagulation, tests, and biochemical testing. Also The patients' vital status, length of hospital stay, and demographic data were also compared between the two of groups of survivors and non-survivors were the patients' demographic information, days spent in the hospital, and vital status. Children, pregnant women, and patients who were

in hospitals for other ARDS-related conditions were not included. 65 years of age or older were considered to be older. All patients had throat swabs obtained at the time of admission, and they were all tested using RT-PCR assays by a method that has previously been used to identify SARS-CoV-2 infection.

### Data Management

The majority of the clinical data for this research was obtained on the discharge day of hospitalization in the survivor group and on the death day in the non-survivor group. WHO interim guidance was used to define COVID-19 pneumonia-related ARDS (9).

### Statistical Analysis

The analysis of the data obtained as a result of the research was made in the SPSS 20 statistical package program. In addition to the Kolmogorov-Smirnov test, conformity to the normal distribution was evaluated based on the skewness and kurtosis coefficients and the range of  $\pm 2$ . Parametric data were compared with the Independent Sample t-test and expressed as standard deviation. The homogeneity of the variances was examined by Levene's test. Nonparametric data were compared with the Mann-Whitney U test and expressed as median (Q1-Q3). The relationship between categorical variables was examined with Chi-Square. Receiver Operative Characteristics (ROC) analysis was used to determine the cut-off values in estimating mortality.  $p < 0.05$  was considered statistically significant.

### Results

In this study, from March 31 to December 31, 2020, a total of 509 patients (mean age  $67.25 \pm 16.00$ ; 326 men [64%]; 161 RT-PCR positives [31.6%]) were hospitalized as ARDS in tertiary ICU and were retrospectively enrolled in our study. They completed both thorax CT and laboratory viral nucleic acid testing (RT-PCR assay with throat swab samples). The patient's electronic medical records in our hospital information system were used to obtain the RT-PCR data. Radiologists found that despite having negative RT-PCR findings, radiologists discovered that 348 (68.4%) of the patients showed characteristics that indicated they were extremely vulnerable to COVID-19 despite having negative RT-PCR results. While 232 (45.6%) patients died in the non-survivor group, 277 patients were released (54.4%) as survivors.

WBC, RBC, HGB, Ph, pO<sub>2</sub>, PCO<sub>2</sub>, HCO<sub>3</sub>, PLT, PCT, NEU, ALT, and D-DIMER parameters did not have a significant difference in mortality. ( $p > 0.05$ ) (table 1)

While the ex group's results for albumin, SO<sub>2</sub>, LYM, and MONO are lower, there was no significant difference in mortality for white blood cell (WBC), red blood cell (RBC), hemoglobin (HGB), potential of hydrogen (Ph), partial oxygen pressure (pO<sub>2</sub>), partial carbon dioxide pressure (pCO<sub>2</sub>), bicarbonate (HCO<sub>3</sub>), platelet (PLT), plateletcrit (PCT), neutrophil (NEU), alanine transferase (ALT), and D-dimer indicators. ( $p > 0.05$ ) (Table 1).

Their mean ages, days spent in hospitals, C reactive protein (CRP), red blood cells distribution width (RDW), aspartate transferase (AST), lactate dehydrogenase (LDH), glucose, ferritin, urea, and creatinine levels are considerably higher ( $p < 0.05$ ). Although in the ex group, despite their lower results for albumin, oxygen saturation (SO<sub>2</sub>), lymphocyte (LYM), and monocyte (MONO).

The ROC analysis revealed that the albumin, SO<sub>2</sub>, LYM, and MONO values were significant in ROC analysis, Chi; however, the chi-square assumptions were not made to support the association establishment of a relationship between these parameters and mortality. Sensitivity Table 2 presents the predictive value of many factors in relation to AUC, sensitivity, specificity, AUC, and 95% confidence intervals in predicting mortality of other parameters are shown in Table 2.

In patients with the non-survivor group of ARDS, CRP, RDW, ferritin, urea, LDH, and creatinine values were significantly higher and those on cut-off were related to mortality ( $p < 0.05$ ). The ROC curves of the parameters are shown in Figure 1.

**Table 1.**

Comparison Of Hemogram, Biochemical and Blood Gas Parameters

	Survivor (n=277, %54.4)	Non-Survivor (n=232, %45.6)	All patients (n=509)	p-value
Gender				
Female	74 (%40.4)	109 (%59.6)	183 (%36.0)	0.000 <sup>a,*</sup>
Male	203 (%62.3)	123 (%37.7)	326 (% 64.0)	
	$\bar{X} \pm ss$			
WBC	13.79±6.88	13.54±9+.25	13.68±8.04	0.717
RBC	4.08±0.74	4.02±0.81	4.06±0.77	0.390
HGB	11.53±2.28	11.44±2.27	11.49±2.27	0.648
Albumin	32.91±6.33	29.62±6.22	31.39±6.48	0.000 <sup>b,*</sup>
CRP	53.58±72.62	105.82±85.59	78.22±83.13	0.000 <sup>b,*</sup>
	<b>Median (Q1-Q3)</b>			
Age	62.97±16.59 66 (54-74)	72.36±13.64 75 (66-82)	70 (59-79) 67.25±16.00	0.000 <sup>b,*</sup>
Days of hospitalized	6.46±10.28 2 (1-7)	12.45±18.06 6 (2-15)	4 (1-10) 9.19±14.65	0.000 <sup>b,*</sup>
Ph	7.42 (7.39-7.47)	7.42 (7.37-7.48)	7.42 (7.37-7.47)	0.508
pO <sub>2</sub>	81.4 (49.5-106.4)	70.8 (43.7-96.95)	75.2 (45.25-101.5)	0.079
pCO <sub>2</sub>	39 (34.8-44.3)	40.35 (33.15-48.2)	39.60 (33.9-45.55)	0.342
SO <sub>2</sub>	97.7 (92.8-99.2)	93.8 (83.9-98.75)	97.0 (88.65-99.0)	0.000 <sup>b,*</sup>
HCO <sub>3</sub>	24.02 (21.9-27)	24.02 (21-26.45)	24.02 (21.6-26.9)	0.426
LYM	1.19 (0.79-1.76)	0.84 (0.53-1.25)	1.03 (0.5-1.6)	0.000 <sup>b,*</sup>
PLT	223 (177-276.5)	222 (147-299)	223 (167-288)	0.502
PCT	0.22 (0.18-0.28)	0.23 (0.16-0.31)	0.23 (0.17-0.29)	0.953
NEU	9.63 (7.15-14.87)	9.9 (6.4-14.7)	9.75 (6.95-14.8)	0.362
MONO	0.73 (0.48-1.06)	0.597 (0.3-0.91)	0.66 (0.37-1.04)	0.000 <sup>b,*</sup>
RDW	13.9 (13-15.8)	15.2 (13.8-17.5)	14.45 (13.2-16.7)	0.000 <sup>b,*</sup>
ALT	22 (14-39)	21 (14-45)	22 (14-41)	0.707
AST	29 (19-48)	34 (20-64)	30 (20-54)	0.029 <sup>b,*</sup>
Glukoz	143 (114-176)	152 (112-230)	146 (113-197)	0.045 <sup>b,*</sup>
Ferritin	172.46 (63.58-511.27)	556.33 (283.96-899.41)	369.21 (117.31-779.42)	0.000 <sup>b,*</sup>
Urea	39 (28-58)	66 (41-107)	47 (32-82.5)	0.000 <sup>b,*</sup>
D-dimer	3.18 (1.32-8.19)	2.865 (1.49-5.29)	2.92 (1.4-6.54)	0.485
LDH	309.5 (240-447)	432.5 (311-616)	365 (263.75-525.75)	0.000 <sup>b,*</sup>
Creatinine	0.87 (0.73-1.17)	1.15 (0.78-2.04)	0.97 (0.74-1.47)	0.000 <sup>b,*</sup>

White blood cell (WBC), red blood cell (RBC), hemoglobin (HGB), potential of hydrogen (Ph), partial oxygen pressure (pO<sub>2</sub>), partial carbon dioxide pressure (pCO<sub>2</sub>), bicarbonate (HCO<sub>3</sub>), platelet (PLT), plateaucrit (PCT), neutrophil (NEU), alanine transferase (ALT), C reactive protein (CRP), red blood cells distribution width (RDW), aspartate transferase (AST), lactate dehydrogenase (LDH), oxygen saturation (SO<sub>2</sub>), lymphocyte (LYM), and monocyte (MONO)

<sup>a</sup>Chi-Square test <sup>b</sup>Independent Sample t test/Mann-Whitney U test

\*Statistically significant



Table 2.


Cut-Off Values of Parameters and Their Relation to The Mortality

	AUC (%95 CI)	Cut-Off	P-value	Sensitivity (%)	Specificity (%)
CRP	0.708 (0.661-0.755)	34.65	<b>0.000*</b>	74.2	62.3
RDW	0.653 (0.606-0.700)	14.35	<b>0.000*</b>	65.4	59.6
AST	0.557 (0.506-0.607)	30.50	<b>0.029*</b>	53.3	53.7
Glukoz	0.552 (0.500-0.604)	145.50	<b>0.045*</b>	52.8	52.0
Ferritin	0.698 (0.619-0.778)	343.37	<b>0.000*</b>	67.3	67.1
Urea	0.711 (0.665-0.756)	50.00	<b>0.000*</b>	65.7	69.3
LDH	0.663 (0.609-0.718)	349.50	<b>0.000*</b>	68.5	60.1
Creatinine	0.632 (0.582-0.682)	0.985	<b>0.000*</b>	62.9	62.5
Albumin	0.350 (0.301-0.399)	31.55	<b>0.000*</b>	40.4	40.3
SO <sub>2</sub>	0.404 (0.353-0.455)	96.85	<b>0.000*</b>	40.1	39.7
LYM	0.357 (0.309-0.406)	1.01	<b>0.000*</b>	39.0	38.8
MONO	0.395 (0.345-0.445)	0.655	<b>0.000*</b>	42.9	42.8

		Survivor n (%)	Non-survivor n (%)	X <sup>2</sup> value	p- value
CRP	0-34.640	157 (%73.0)	58 (%27.0)	64.049	<b>0.000*</b>
	34.641 ve üstü	95 (%36.3)	167 (%63.7)		
RDW	0-14.340	164 (%67.2)	80 (%32.8)	31.437	<b>0000*</b>
	14.341 ve üstü	111 (%42.4)	151 (%57.6)		
AST	0-30.490	146 (%57.7)	107 (%42.3)	2.403	0.128
	30.491 ve üstü	126 (%50.8)	122 (%49.2)		
Glukoz	0-145.490	141 (%56.6)	108 (%43.4)	1.177	0.283
	145.491 ve üstü	130 (%51.8)	121 (%48.2)		
Ferritin	0-343.360	53 (%59.6)	36 (%40.4)	21.789	<b>0.000*</b>
	343.361 ve üstü	26 (%26.0)	74 (%74.0)		
Urea	0-49.00	190 (%70.6)	79 (%29.4)	61.533	<b>0.000*</b>
	49.01 ve üstü	84 (%35.7)	151 (%64.3)		
LDH	0-349.490	119 (%67.2)	58 (%32.8)	31.327	<b>0.000*</b>
	349.491 ve üstü	79 (%38.5)	126 (%61.5)		
Creatinine	0-0.984	173 (%66.8)	86 (%33.2)	32.556	<b>0.000*</b>
	0.985 ve üstü	104 (%41.6)	146 (%58.4)		

White blood cell (WBC), red blood cell (RBC), hemoglobin (HGB), potential of hydrogen (Ph), partial oxygen pressure (pO<sub>2</sub>), partial carbon dioxide pressure (pCO<sub>2</sub>), bicarbonate (HCO<sub>3</sub>), platelet (PLT), plateaucrit (PCT), neutrophil (NEU), alanine transferase (ALT), C reactive protein (CRP), red blood cells distribution width (RDW), aspartate transferase (AST), lactate dehydrogenase (LDH), oxygen saturation (SO<sub>2</sub>), lymphocyte (LYM), and monocyte (MONO).  
 \* Chi-Square analysis. The values in bold are statistically significant. AUC: Area under the curve



C reactive protein (CRP), red blood cells distribution width (RDW), lactate dehydrogenase (LDH)

Figure 1. Receiver operating characteristic (ROC) curve for mortality



## Discussion

In this retrospective study, the laboratory characteristics associated with clinical outcomes in patients with COVID-19 pneumonia-related ARDS and those who progressed from ARDS to death between two groups as a survivor and non-survivor group were evaluated. We aimed to predict the laboratory parameters that are linked to the onset of ARDS and the progression of ARDS to mortality in COVID-19 pneumonia patients. The older age and days of hospitalized stay were even associated with a higher risk of developing ARDS and mortality; this was not statistically significant. In patients with the non-survivor group of ARDS; CRP, RDW, LDH, ferritin, urea, and creatinine values were significantly higher and related to mortality ( $p < 0.05$ ).

The illness caused by SARS-CoV2/COVID-19 spread rapidly, and significant studies have been done to determine which patients will be affected and what their clinical outcomes would be. We know that this virus mostly impacted the respiratory system, with some patients quickly developing acute respiratory distress syndrome (ARDS) which was mostly related to mortality; other organ functions were less affected (11). Thus, it is necessary for early detection and accurate therapy of COVID-19 pneumonia-related ARDS.

Patients with ARDS have been seen in ICUs across the world. Around 5% of patients infected with the new 2019 coronavirus disease necessitate hospitalization owing to ARDS, with a case-fatality rate ranging from 30% to 60% (11-13). Previous observational studies in Turkey found death rates ranging from 8.5 percent to 50%, depending on the healthcare environment, the age of the study group, and the severity of the condition (14-16). These studies were generally done in a single-center setting with a small number of patients. One big research, which used Ministry of Health records and included 16,942 hospitalized old people, found death rates ranging from 17.9% to 32.2% depending on when public limitations were in place (15). The research, however, did not give any clinical data about the patients. Our study evaluated a fatality rate of 45.5%. The groups in our research were not limited to mild to moderate cases but included a wide spectrum of severe patients with ARDS. This might explain why the death rate is so high when compared to prior findings from Turkey and other countries (17-19).

Several studies have evaluated the risk factors for mortality (20-23). The most well-known predictor of death in older age and countries with significant old populations have been proven to have higher case-fatality rates. The in-hospital mortality rate for patients aged 80 and over was estimated to be 32.8 percent in Turkey (15,16). Similarly, the non-survivors and survivors in our research had mean ages of 72.3 and 62.9 years, demonstrating that age was an independent variable associated with death. The median hospital stay was 6.4 days in the survivor group and 12.4 in the non-survivor group, as expected. Older age and days of hospital stay were significantly higher in the non-survivor group than in the survivor group but these were not predictable for mortality. Low immune response and comorbidities are all age-related disorders that may play a role infor the increased risk.

Some hematological and biochemical parameters about the prognosis of COVID-19, multiple recent studies have researched laboratory features of hospitalized patients. (17-19,23) Chidambaram et al. (22) looked at clinical and laboratory indicators related to mortality in a meta-analysis utilizing 109 published publications, 42 of which looked at mortality. Increased levels of CRP, LDH, and D-dimer were associated with a higher risk of severe disease and death. Huang et al. (23) found that increased serum CRP, PCT, D-dimer, and ferritin were linked with a poor outcome in a meta-analysis involving a total of 5350 patients. Another meta-analysis found that procalcitonin had the best predictor of mortality and disease severity (24). This may be caused by bacterial coinfection and cytokine storm according to the authors. In that study, parameters related to mortality were respiratory failure, high WBC-CRP-creatinine-LDH-D dimer-lactate, and low albumin, thrombocytopenia, and lymphopenia. In a recent study in Turkey, BUN and albumin levels at admission, as well as D-dimer and procalcitonin levels during follow-up, were shown to be linked with mortality (25). We found that CRP, LDH, RDW, ferritin, urea, and creatinine values were significantly higher and related to mortality like these studies. These parameters may be linked to the cytokine storm triggered by a viral infection, whereas coagulation activation is related to the long-term inflammatory response. Acute renal impairment caused by the infection, hypoxia, and shock might have resulted in elevated urea and creatinine levels.

Furthermore, because our study was single-center and had a limited sample size, our findings may not apply to all COVID-19 pneumonia-related ARDS patients. Secondly, we did not evaluate the comorbidities that can affect mortality. Also, the findings relied on data that were recorded at the time of hospitalization in the ICU, so there were no follow-up parameters. Finally, patients' ventilator parameters were not noted for both two groups even if that setting is being recommended to personalize at the bedside. To investigate the phenotypic, larger cohort studies are needed for ARDS caused by COVID-19.

## Conclusion

In this study, we found that various laboratory indicators were linked to death in COVID-19 pneumonia-related ARDS and that physicians/clinicians should consider these factors while managing these patients. After these findings have been validated in prospective research, it may be advantageous to develop algorithms based on them.

**Ethics Committee Approval:** This study was approved by the Ethics Committee of Bolu Abant İzzet Baysal University, (Approval No: 2020/327).

**Informed Consent:** Written consent was obtained from the participants.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors declared no financial support.

**Author Contributions:** Idea/Concept: E.O., M.E.D.; Design: X.X, Y.Y.; Supervision: E.O, S.O.; Funding: E.O, S.O.; Materials: M.E.D., S.O.; Data Collection/Processing: E.O., S.O, M.E.D; Analysis/Interpretation: D.D.K, M.K., Z.B.; Literature Review: M.K, D.D.K, Z.B.; Drafting/Writing: E.O.; Critical Review: M.K, D.D.K., Z.B. The authors have accepted responsibility for the entire content of this manuscript and approved its submission.

## References

1. WHO Coronavirus Disease (COVID-19) Dashboard [Internet], 2021 [accessed 2021 Oct 29]. Available from: <https://covid19.who.int/>.
2. Ministry of Health, Republic of Turkey. COVID-19 web page of the Republic of Turkey, Ministry of Health [Internet]. 2021 [accessed 2021 Oct 29], <https://covid19.saglik.gov.tr>.
3. Worldometer, Countries where covid-19 has spread [Internet] [accessed 2021 Oct 29], <https://www.worldometers.info/coronavirus/countries-where-coronavirus-has-spread>
4. S.Matta, et al., Morbidity and mortality trends of COVID-19 in top 10 countries, *Indian J. Tubercul.* 67 (2020) 167–172.
5. Zhang J, et al., Hospitals' responsibility in response to the threat of infectious disease outbreak in the context of the coronavirus disease 2019 pandemic: implications for low and middle-income countries, *Glob. Health J.* 4 (2020) 113–117.
6. Watson J, et al., Interpreting a COVID-19 test result, *BMJ* 369 (2020), m1808.
7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. doi:10.1016/S0140-6736(20)30183-5
8. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507- 513. doi:10.1016/S0140-6736(20)30211-7
9. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382:727–33. 4. World Health Organization. COVID-19 outbreak. <https://www.who.int>.
10. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020.
11. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region. *Italy JAMA*. 2020;24:122.
12. Cao J, Hu X, Cheng W, et al. Clinical features and short-term outcomes of 18 patients with coronavirus disease 2019 in intensive care unit. *Intensive Care Med*. 2020;46:851–3.

13. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single centered, retrospective, observational study. *Lancet Respir Med.* 2020;2600: 1–7.
14. Y.Varol, et al., The impact of Charlson comorbidity index on mortality from SARSCoV-2 virus infection and a novel COVID-19 mortality index: CoLACD, *Int. J. Clin. Pract.* (2020), <https://doi.org/10.1111/ijcp.13858>.
15. G. Aksel, et al., Early predictors of mortality for moderate to severely ill patients with COVID-19, *Am. J. Emerg. Med.* (2020), <https://doi.org/10.1016/j.ajem.2020.08.076>.
16. G. Onder, et al., Case-fatality rate and characteristics of patients dying about COVID-19 in Italy, *J. Am. Med. Assoc.* 323 (2020) 1775–1776.
17. A. Bahl, et al., Early predictors of in-hospital mortality in patients with COVID-19 in a large American cohort, *Intern. Emerg. Med.* 15 (2020) 1485–1499.
18. L.Q. Li, et al., COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis, *J. Med. Virol.* 92 (2020) 577–583.
19. S. Richardson, et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, *J. Am. Med. Assoc.* 323 (2020) 2052–2059.
20. Jin M, et al., Gender differences in patients with COVID-19: focus on severity and mortality, *Front. Public. Health* 8 (2020) 152.
21. Chidambaram V, et al., Factors associated with disease severity and mortality among patients with COVID-19: a systematic review and meta-analysis, *PloS One* 15 (2020), e0241541.
22. Huang I, et al., C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis, *Ther. Adv. Respir. Dis.* 14 (2020), 1753466620937175.
23. Özsari, S., Özsari, E., Demirkol, M.E. Comparison of neutrophil-lymphocyte ratio, platelet lymphocyte ratio, and mean platelet volume and PCR test in COVID-19 patients. *Revista da Associação Médica Brasileira*, 67(2021), 40-45.
24. P.R. Martins-Filho, et al., Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data, *Eur. J. Intern. Med.* 76 (2020) 97–99.
25. Kokturk, N., Babayigit, C., Kul, S., Cetinkaya, P. D., Nayci, S. A., Baris, S. A., Bayram, H. (2021). The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients. *Respiratory Medicine*, 183, 106433.



## Comparison Of Three Methods for Calculation of Sacroiliac Joint Index in Different Age Groups in Bone Scintigraphy

Kemik Sintigrafisinde Farklı Yaş Gruplarında Sakroiliak Eklem İndeksinin Hesaplanmasında Kullanılan Üç Yöntemin Karşılaştırılması

Ebru SALMANOĞLU <sup>1\*</sup> 

<sup>1</sup> Adana City Hospital, Nuclear Medicine Clinic, Adana, Türkiye

Geliş Tarihi (Received): 08.05.2024

Kabul Tarihi (Accepted): 05.08.2024

Yayın Tarihi (Published): 29.08.2024

### Abstract

**Objective:** The aim of this study is to evaluate three techniques for calculating the sacroiliac joint (SIJ) index by bone scintigraphy in patients.

**Materials and Methods:** Patients (n:160) who did not exhibit abnormalities on bone scan were analyzed and were divided into 4 groups; 3-20 years, 21-40 years, 41-60 years, and 61-86 years, respectively. Irregular and rectangular regions of interest (ROI) were used for the first and second methods, respectively. Horizontal rectangular ROI was selected for the last technique. The SIJ index was calculated by the following formula: SIJ count/sacrum count.

**Results:** There was no difference between the averages of all three methods according to the right and left SIJ index ( $p>0.05$ ). The averages of all SIJ values differed for the three methods ( $p<0.05$ ). The average of the first method's values for all three situations was lower than the averages of the other two methods' values ( $p<0.05$ ). The first technique had a lower mean for the right SIJ index value than the other two techniques ( $p<0.05$ ). The average of females was lower than males for all SIJ index values. The lowest average was detected at the age of 61 and above for three methods for both genders. All methods differed according to age ( $p<0.05$ ). A relationship was detected between the age and all three index values of all techniques.

**Conclusion:** A threshold value for each method should be identified using a fixed reference point for each age group taking into account gender.

**Keywords:** Sacroiliac joint index, Bone scintigraphy, Sacroiliitis, Region of interest, Tc-99m MDP.

&

### Öz

**Amaç:** Bu çalışmanın amacı hastalarda kemik sintigrafisi ile sakroiliak eklem (SİE) indeksinin hesaplanmasına yönelik üç tekniğin değerlendirilmesidir.

**Gereç ve Yöntemler:** Kemik sintigrafisinde anormallik izlenmeyen hastalar (n:160) analiz edildi ve 4 gruba ayrıldı; sırasıyla 3-20 yaş, 21-40 yaş, 41-60 yaş, 61-86 yaş. Birinci ve ikinci yöntem için sırasıyla düzensiz ve dikdörtgen ilgi alanı (ROI) kullanıldı. Son yöntem için yatay dikdörtgen ROI seçildi. SİE indeksi şu formülle hesaplandı: SİE sayımı/sakrum sayımı.

**Bulgular:** Üç yöntemde sağ ve sol SİE indeksi ortalamaları arasında fark yoktu ( $p>0,05$ ). Tüm SİE değerlerinin ortalamaları üç yöntem için farklılık gösterdi ( $p<0,05$ ). Her üç durum için de birinci yöntemin değerlerinin ortalaması diğer iki yöntemin değerlerinin ortalamasından düşüktü ( $p<0,05$ ). Sağ SİE indeksi değeri için ilk metodun ortalaması diğer iki yöntem göre daha düşüktü ( $p<0,05$ ). Kadınların ortalaması tüm SİE indeks değerleri için erkeklerden daha düşüktü. Her iki cinsiyette de üç yöntem için en düşük ortalama 61 yaş ve üzerinde tespit edildi. Tüm yöntemler yaşa göre farklılık gösterdi ( $p<0,05$ ). Bütün metodlarda yaş ile her üç indeks değeri arasında korelasyon tespit edildi.

**Sonuç:** Her yöntem için cinsiyet dikkate alınarak her yaş grubu için sabit bir referans noktası kullanılarak bir eşik değeri belirlenmelidir.

**Anahtar Kelimeler:** Sakroiliak eklem indeksi, Kemik sintigrafisi, Sakroileit, İlgi alanı, Tc-99m MDP.

**Atf/Cite as:** Özşarı E, Demirkol ME, Özşarı S, Kaya M, Kocadağ D, Baysal Z. COVID-19 Pneumonia-Related ARDS – Can We Predict Mortality with Laboratory Parameters?. Abant Med J. 13(2):67-77. doi:10.47493/abantmedj.1416495

Copyright © Published by Bolu Abant İzzet Baysal University, Since 2022 – Bolu

\*Sorumlu Yazar (Corresponding Author): Ebru Salmanoğlu, e-mail: ebrusalmanoğlu@yahoo.com



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

## Introduction

The Sacroiliac joint (SIJ) provides a connection of the right ilium, sacrum, and left ilium. This joint also ensures body weight is transferred to the lower extremities. This joint's anatomy has a wide spectrum in adults (1). SIJ structure varies according to age, gender, and race. SIJ is more flexible in women to facilitate a baby's transition during birth. Therefore, women are more susceptible to stress on the structures surrounding the joint. On the other hand, SIJ is stronger in men, and as a result of that more load is added to the joint (1-4).

Sacroiliitis is an inflammatory disease and it causes SIJ dysfunction and pain. Patients generally complain of lumbar pain and ~ 70% of individuals are affected throughout their lifetime. While sports injuries and trauma cause pain in young patients, joint degeneration causes in an elderly population (1-4).

It can be difficult to differentiate SIJ pain from various diseases that cause similar symptoms. Patients with SIJ pain usually consult physicians with deep-rooted thigh pain that radiates to the lower extremities. The pain can be unilateral or bilateral and might increase with sitting down, long walking, or walking uphill. Therefore, detailed medical history is very important for diagnosis. Various tests are used to reveal SIJ pain during physical examination (1-3).

Dysfunction of this joint affects the life quality of individuals. Therefore, correct diagnosis is important. Imaging modalities play a vital role in sacroiliitis diagnosis. Various imaging methods have been used to demonstrate anatomical changes in sacroiliitis. Direct radiography is generally a preferred method by clinicians due to its easy accessibility. Furthermore, it is also a safe method and utilized with several advantages such as low radiation dose and low cost (4-5).

Computed Tomography (CT) provides detailed information about the SIJ anatomy, soft tissue surrounding the joint, and adjacent structures compared to radiography. It can show erosion, sclerosis, and narrowing of joint space (3-4).

Magnetic Resonance Imaging (MRI) demonstrates the early and inflammatory stage of sacroiliitis due to its high resolution. Therefore, it is accepted as the gold standard for the diagnosis of sacroiliitis. Furthermore, MRI usually detects bone marrow edema which is a key finding in active disease. It can visualize erosion, and changes in SIJ and soft tissues (4-7).

Nuclear medicine imaging methods can also be helpful for the evaluation of early sacroiliitis. Technetium (Tc)-99m labeled methylene diphosphonate (MDP) bone scintigraphy is the most commonly used nuclear medicine scan for sacroiliitis. Bone scintigraphy can detect early inflammatory and metabolic changes earlier than plain radiography (4,8,9). This method can also show the width of inflammation. Whole-body imaging is performed with a bone scan. Therefore, it provides valuable information about affected other joints in patients, especially with arthritis. However, this method is not specific and does not provide detailed anatomical information. It is combined with an X-ray or MRI.

Scintigraphic images are evaluated visually. The area where the radioactive substance accumulates pathologically is regarded as positive. SIJ value that is obtained by the ratio of SIJ counts to sacrum count as a quantitative parameter increases its specificity (10). If the SIJ count is greater than the sacrum count, it has clinical significance for the diagnosis of sacroiliitis.

Various studies that compare different regions of interest (ROI) methods in different age groups for the determination of the normal values of the SIJ index were reported in the literature (11-12).

From this point of view, we aimed to investigate the variability of normal values of the SIJ index according to different ROI methods. Therefore, we separated the cases into 4 groups based on these studies. It is known that Tc-99m MDP is physiologically distributed in the SIJ. It was reported that the normal SIJ value of each population is different. Based on this information, we also aimed to investigate the factors affecting the SIJ value in individuals whose bone scintigraphy was reported as normal in our society. Therefore, we analyzed whether this index varies according to age, gender, and laterality.



## Materials and Methods

Patients who underwent bone scintigraphy from May 2015 to June 2016 at Kahramanmaraş Sutcu Imam University, Faculty of Medicine, Department of Nuclear Medicine were analyzed. Local Ethics Committee approval was obtained with decision number 16 dated 29.06.2016.


Patients with a history of inflammatory arthritis, low back pain, orthopedic surgery, and multiple osteoblastic bone metastasis were excluded from the study.

One hundred sixty patients were included in this cross-sectional research. Patients who did not have pathological findings on bone scintigraphies were included in this study to assess normal values of the SIJ index as a control.

Scintigraphic imaging was carried out 3 hours after intravenous administration of 740 MBq Tc-99m MDP for adults. The pediatric dosage was calculated according to the guidelines. Imaging was performed with a dual-headed gamma camera (GE Healthcare Discovery NM630) equipped with a low-energy general-purpose collimator. Whole body bone scintigraphy (128x512 matrix) and static images (256x256 matrix) were performed for computer analysis.

Posterior pelvic images were used for analysis. Three different ROI methods were selected based on a literature search.


Irregular-shaped ROI was chosen for the first method. In this method, manual drawings were made around both SIJ and sacrum, separately (Figure 1). The average counts obtained from these drawings were recorded.



**Figure 1.** Irregular ROI method. Three ROIs are seen on both sacroiliac joints and sacrum were manually drawn in posterior pelvis image of bone scintigraphy.




Rectangular-shaped ROI was chosen for the second technique and it was automatically placed on the right SIJ, sacrum, and left SIJ, separately (Figure 2). The average counts obtained from these bones were recorded.



**Figure 2.** Rectangular ROI method. Same shaped rectangular ROI were placed on both sacroiliac joints and sacrum in posterior pelvis image of bone scintigraphy.

In the third method, a horizontal rectangular ROI was selected. This ROI was automatically placed on the same bone structures. A graph that shows profile peak counts of these bones was obtained and recorded (Figure 3).



**Figure 3.** Horizontal rectangular ROI method. A horizontal rectangular ROI was placed on both sacroiliac joints and sacrum in posterior pelvis image of bone scintigraphy. Three separate peaks that shows maximum counts on the profile for both sacroiliac joints and sacrum.

The SIJ index was calculated by the following formula: SIJ count/sacrum count in all three methods.

### Statistical Analysis

Statistical Package for the Social Sciences software (IBM SPSS Statistics for Windows, Version 25.0 IBM Corp., Chicago, IL, USA) was used for data analysis. Outlier analysis was performed to check the normality of the data and were excluded from the evaluation. To determine whether the data was suitable for normal distribution, it was first assessed with Kolmogorov-Smirnov/Shapiro-Wilk tests. Normality tests were also supported by skewness-kurtosis and a Q-Q plot graph. Descriptive data were expressed as number (n), percentage (%), and mean±SD (standard deviation) values. In cases where the normality assumption was met, paired sample t-test and if not met Mann Whitney U test, one of the non-parametric tests, were performed for two groups. One-way analysis of variance (ANOVA, F) test was performed to compare the means in more than two groups. Correlation analysis was performed to analyze the relationship between individual variables. Pearson correlation analysis was performed for normally distributed groups. A value of p < 0.05 was considered significant statistically.

### Results

74 (46,2%) patients were females and 86 (53.8%) patients were males. The average age of the patients differed between females and males (p<0.05). The average age of males (90,54) was higher than that of females (68.83). The mean age of cases was found to be 51,85±18 years.

According to studies in the literature, patients were separated into 4 groups with an interval of 20 years. There were 12 patients in the first group (aged 3 to 20 years), 29 patients in the second group (aged 21 to 40 years), 54 patients in the third group (aged 41 to 60 years), and 65 patients in the fourth group (aged 61 to 86 years).

The averages of the three techniques were not different according to the right and left SIJ index as shown in Table 1 (p>0.05).

**Table 1.**

Evaluation of the averages of irregular-shaped ROI, rectangular-shaped ROI, horizonral rectangular ROI methods according to right SIJ index and left SIJ index

Variables	Groups	n	mean±SD	p value
Irregular-shaped ROI	Right SIJ index	160	1,03±0,11	0,681
	Left SIJ index	160	1,03±0,10	
Rectangular-shaped ROI	Right SIJ index	160	1,12±0,12	0,996
	Left SIJ index	160	1,12±0,11	
Horizontal rectangular ROI	Right SIJ index	160	1,13±0,16	0,169
	Left SIJ index	160	1,14±0,17	

ROI: Region of interest, SIJ: Sacroiliac joint

The averages of the right, left, and mean SIJ index values of the patients differed for the three techniques (p<0.05). The average of the first method values for all three situations was found to be statistically significantly lower than the average of the other two techniques' values (p < 0.05) (Table 2).

**Table 2.**

Comparison of average of irregular-shaped ROI, rectangular-shaped ROI, horizontal rectangular ROI methods according to right, left and mean SIJ values


Variables	Groups	n	mean±SD	F	p value
Right SIJ index	Irregular-shaped ROI	160	1,03±0,10	28,893	<b>0,000*</b>
	Rectangular-shaped ROI	160	1,12±0,11		
	Horizontal rectangular ROI	160	1,13±0,16		
Left SIJ index	Irregular-shaped ROI	160	1,03±0,10	29,672	<b>0,000*</b>
	Rectangular-shaped ROI	160	1,12±0,11		
	Horizontal rectangular ROI	160	1,14±0,17		
Mean SIJ index	Irregular-shaped ROI	160	1,03±0,09	31,415	<b>0,000*</b>
	Rectangular-shaped ROI	160	1,12±0,11		
	Horizontal rectangular ROI	160	1,13±0,16		

F test; \*p<0.05; ROI: Region of interest, SIJ: Sacroiliac joint.

The mean of three techniques and right, left, and mean SIJ index values were analyzed. The first method had a significantly lower mean for the right SIJ index value than the other two methods (p<0.05).

All SIJ index values were analyzed according to gender. The average of females was lower than males for all three SIJ index values. While the average of females was 1.09±0.14 for the right SIJ index, 1.08±0.14 for the left SIJ index, 1.08±0.13 for the mean SIJ index, the average of males was 1.10±0.13, 1.11±0.13, 1.10±0.13, respectively.

All SIJ index values according to gender were evaluated based on age (Graph 1). The lowest average was detected at the age of 61 and above for all three methods for females and males.



**Graph 1.** Graphical presentation of right SIJ index, left SIJ index and mean SIJ index values according to gender, based on age.

It was determined that all methods differed according to age as shown in Table 3 ( $p < 0.05$ ). The average of the first group was higher than the third and fourth groups, and the average of the second group was higher than the fourth group for the first and second methods. The average of the first group was higher than the second, third, and fourth groups, and the average of the second group was higher than the fourth group for the third method ( $p < 0.05$ ).

**Table 3.**

Evaluation of the averages of the irregular-shaped ROI, rectangular-shaped ROI, horizontal rectangular ROI methods according to age

Methods	Age-Groups	n	mean±SD	F	p value
Irregular-shaped ROI	Group 1	12	1,13±0,11	7,662	0,000*
	Group 2	29	1,06±0,10		
	Group 3	54	1,02±0,09		
	Group 4	65	1,00±0,08		
Rectangular-shaped ROI	Group 1	12	1,23±0,12	8,773	0,000*
	Group 2	29	1,17±0,11		
	Group 3	54	1,11±0,10		
	Group 4	65	1,09±0,09		
Horizontal rectangular ROI	Group 1	12	1,34±0,13	11,816	0,000*
	Group 2	29	1,18±0,16		
	Group 3	54	1,12±0,15		
	Group 4	65	1,08±0,13		

ANOVA (F test); \* $p < 0.05$ ; ROI: Region of interest, SIJ: Sacroiliac joint.

A negative medium-level relationship was detected between the patient's age and the first method's right SIJ index value ( $p < 0.05$ ). A negative low-level relationship was detected between the patient's age and the first method left SIJ index value ( $p < 0.05$ ).

A negative medium-level relationship was detected between the patient's age and the second method's right SIJ index value ( $p < 0.05$ ). A negative medium-level relationship was found between the patient's age and the second method left SIJ index value ( $p < 0.05$ ).

A negative medium-level relationship was detected between the age of the patient and the third method's right SIJ index value ( $p < 0.05$ ). A negative medium-level relationship was detected between the patient's age and the third method left SIJ index value ( $p < 0.05$ ).

There was a difference between the averages of all three techniques for the 0-20 age group ( $p < 0.05$ ). The difference was found between the first and third techniques ( $p < 0.05$ ).

There was a difference between the averages of all three techniques for the 21-40 age group ( $p < 0.05$ ). The difference was found between the first and third techniques; the first and second techniques ( $p < 0.05$ ).

There was a difference between the averages of all three techniques for the 41-60 age group ( $p<0.05$ ). There was a difference between the first and third techniques; the first and second techniques ( $p<0.05$ ).

There was a difference between the averages of all three techniques for the age group of 61 years and above ( $p<0.05$ ). There was a difference between the first and third techniques; the first and second techniques ( $p<0.05$ ) (Table 4).

**Table 4.**

Evaluation of the averages of irregular-shaped ROI, rectangular-shaped ROI, horizontal rectangular ROI methods based on four age groups.

Age groups	Group	n	mean±SD	F	p value
0-20 age group	Irregular-shaped ROI	12	1,13±0,11	8,531	0,001*
	Rectangular-shaped ROI	12	1,23±0,12		
	Horizontal rectangular ROI	12	1,34±0,14		
21-40 age group	Irregular-shaped ROI	29	1,06±0,10	7,353	0,001*
	Rectangular-shaped ROI	29	1,17±0,11		
	Horizontal rectangular ROI	29	1,18±0,17		
41-60 age group	Irregular-shaped ROI	54	1,02±0,09	10,999	0,000*
	Rectangular-shaped ROI	54	1,11±0,10		
	Horizontal rectangular ROI	54	1,12±0,15		
≥ 61 age group	Irregular-shaped ROI	69	1,01±0,08	12,991	0,000*
	Rectangular-shaped ROI	69	1,10±0,10		
	Horizontal rectangular ROI	69	1,07±0,14		

F test; \* $p<0.05$ ; ROI: Region of interest

## Discussion

Quantitative sacroiliac bone scans have been used for a long time (13).

In this study, a total of 160 patients with normal bone scintigraphy were retrospectively evaluated. Three ROI methods were used to calculate quantitative SIJ index in four different age groups.

When the averages of the three methods were evaluated according to laterality in this study, no significant difference was found ( $p>0.05$ ) (Table 1).



The results of this study showed that right, left, and mean SIJ index values of the three methods were different ( $p<0.05$ ) (Table 2). The mean value of the rectangular-shaped ROI method was lower than other methods in our study. In the first method, unlike the second and third methods, all counts from the bone structure are obtained. Additionally, the choice of count type and the distribution of radioactivity in the bone may have caused this result. Furthermore, the second and third methods were more practical than the first method.

All SIJ index values were analyzed according to gender in this study. The results showed that females had lower SIJ index values than males. It may be caused by anatomical and physiological differences in the female and male pelvis. The male pelvis is adapted for weight bearing. Therefore, the male pelvis is narrower and the joint surface is wider. Unlike the male pelvis, the female pelvis is wider to facilitate birth (1-4). This can also be explained by the hormonal status of females.

This study showed that the age group  $\geq 61$  had the lowest SIJ values in both genders (Graph 1). The mean SIJ value in females was  $1.02\pm 0.11$  for the right side, and  $1.02\pm 0.12$  for the left side. The mean SIJ value in male was found  $1.06\pm 0.10$  and  $1.08\pm 0.11$  for right and left side, respectively. Radioactive agent uptake is related to blood flow and osteoblastic activity. Bone metabolism decreases with increased age. This result is correlated with this physiological process.

In this study, we found that three ROI drawing techniques in four groups were significantly different from each other (Table 3). The influence of ROI selection is important due to the variability of radiopharmaceutical distribution in the areas we used as a reference.

A negative significant association between age and right/left SIJ index values was found using all three methods in this study ( $p<0.05$ ). This result shows that age affects the SIJ index. Osteoblast activity decreases with aging, thus bone density decreases. At the same time, the SIJ cartilage becomes weaker and degenerative changes can occur in the joint. We believe that the physiological aging process may cause this result.

The average value range of the SIJ index of the three methods was determined as follows: 1.13-1.34 for the first group, 1.06-1.18 for the second group, 1.02-1.12 for the third group, 1.01-1.10 for the fourth group in this study (Table 4). ROI drawing methods may cause different results in different age groups. Differences in bone density, cartilage structure and ligaments of the SIJ as well as SIJ stability in children and adults can also lead to this result.

There are different results on this subject in the literature. In a research study, four different techniques were compared to calculate the SIJ index in a healthy group ( $n=100$ ). Tiwari et al. reported that there was no difference between these methods in the SIJ index (11). Therefore, the authors underlined that the selection of ROI did not have importance in calculating this index. Elderly patients had the lowest SIJ values (11).

The same authors also stated that SIJ values were changed between 1.06 and 1.36 (11). Additionally, in another study, authors documented that normal SIJ values ranged between 0.9 and 1.14 in eighty-two cases (13). Normal SIJ values can change in every population.

Reyhan et al. reported that right SIJ was lower than left in both genders in 197 patients without any disease (12). SIJ value decreased with increasing age. The authors also stated that body mass index (BMI) and number of births affected the SIJ value. SIJ was decreased with increasing BMI in women.

SIJ value was higher in females in the first method using the sacrum as a background in research that was performed in pediatric patients ( $n=79$ ). However, no difference was found in the second method using the L5 vertebra as background. Moreover, SIJ values were lower in the second method in this study (15).

Rectangular ROI was used to calculate the SIJ index in a study conducted on 335 people. The lowest value was obtained in the group aged 5 and under (16).

Min. et al. retrospectively evaluated bone scans in patients ( $n=53$ ) and the SIJ to sacrum ratio was found helpful (17).

Yoon et al. evaluated the diagnostic performance of quantitative single photon emission computed tomography (SPECT)/CT for identifying sacroiliitis. SPECT/CT had 87.5% sensitivity and 56.5% specificity. SIJ/sacrum ratio can be helpful for patients in whom MRI is contraindicated (18).



There was a medium correlation between SPECT/CT and MRI in a study that was performed in 53 patients. The authors concluded that this method might have a role in the diagnosis of active sacroiliitis (19).

In addition to conventional imaging methods, studies related to deep learning have been reported in the literature. Lee et al. developed and evaluated an artificial intelligence (AI) model using MRI images to show sacroiliitis in 296 patients. The authors reported that this model might be used for other clinical conditions (20).

An AI model was developed using pelvic radiographs from patients by Li et al. (21). This model was found to be helpful for diagnosis and management of sacroiliitis.

Bordner et al. developed a deep-learning model using MRI images of patients to show active sacroiliitis. The authors concluded that the diagnostic performance of this AI model was high for the detection of BME (22).

Limitations of this study were a low number of patients and a number of births, body mass index which might affect SIJ values could not be evaluated.

## Conclusion

Despite advances in imaging technologies, bone scintigraphy still maintains its importance in clinical practice. This method has been used for various clinical indications including detection of sacroiliitis. Bone scintigraphy is an easy-accessible, low cost and sensitive method. SIJ index is a quantitative parameter that increases, the bone scan's specificity. Due to SIJ's complex anatomy and the physiological distribution of the radiopharmaceutical, various factors might affect SIJ index values in individuals. Depending on the ROI selection, the normal SIJ index value varies in the same age group. For this reason, each society should know its own SIJ values considering other factors.

**Ethics Committee Approval:** The study was approved by the Sutcu Imam University Local Ethics Committee (date:29.06.2016 and decision number:16).

**Informed Consent:** Written consent was obtained from the participants.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors declared no financial support.

**Author Contributions:** Idea/Concept: E.S.; Design: E.S.; Supervision: E.S.; Funding: E.S.; Materials: E.S.; Data Collection/Processing: E.S.; Analysis/Interpretation: E.S.; Literature Review: E.S.; Drafting/Writing: E.S.; Critical Review: E.S. The authors have accepted responsibility for the entire content of this manuscript and approved its submission.

## References

1. Gartenberg A, Nessim A, Cho W. Sacroiliac joint dysfunction: pathophysiology, diagnosis, and treatment. *Eur Spine J.* 2021; 30(10): 2936-43.
2. Falowski S, Sayed D, Pope J, Patterson D, Fishman M, Gupta M, et al. A Review and Algorithm in the Diagnosis and Treatment of Sacroiliac Joint Pain. *J Pain Res.* 2020; 13: 3337-48.
3. Lee A, Gupta M, Boyinepally K, Stokey PJ, Ebraheim NA. Sacroiliitis: A Review on Anatomy, Diagnosis, and Treatment. *Adv Orthop.* 2022; 2022: 3283296.
4. Al-Mnayyis A, Obeidat S, Badr A, Jouryeh B, Azzam S, Al Bibi H, et al. Radiological Insights into Sacroiliitis: A Narrative Review. *Clin Pract.* 2024; 14(1):106-21.
5. Carneiro BC, Rizzetto TA, Silva FD, da Cruz IAN, Guimarães JB, Ormond Filho AG, et al. Sacroiliac joint beyond sacroiliitis-further insights and old concepts on magnetic resonance imaging. *Skeletal Radiol.* 2022; 51(10): 1923-35.
6. Østergaard M. MRI of the sacroiliac joints: what is and what is not sacroiliitis? *Curr Opin Rheumatol.* 2020; 32(4): 357-64.
7. de Winter J, de Hooge M, van de Sande M, de Jong H, van Hoeven L, de Koning A, et al. Magnetic Resonance Imaging of the Sacroiliac Joints Indicating Sacroiliitis According to the Assessment of

- SpondyloArthritis international Society Definition in Healthy Individuals, Runners, and Women With Postpartum Back Pain. *Arthritis Rheumatol.* 2018; 70(7): 1042-48.
8. Van den Wyngaert T, Strobel K, Kampen WU, Kuwert T, van der Bruggen W, Mohan HK, et al; EANM Bone & Joint Committee and the Oncology Committee. The EANM practice guidelines for bone scintigraphy. *Eur J Nucl Med Mol Imaging.* 2016; 43(9): 1723-38.
  9. Gheita TA, Azkalany GS, Kenawy SA, Kandeel AA. Bone scintigraphy in axial seronegative spondyloarthritis patients: role in detection of subclinical peripheral arthritis and disease activity. *Int J Rheum Dis.* 2015; 18(5): 553-9.
  10. Koç ZP, Kin Cengiz A, Aydın F, Samancı N, Yazısız V, Koca SS, et al. Sacroiliac indices increase the specificity of bone scintigraphy in the diagnosis of sacroiliitis. *Mol Imaging Radionucl Ther.* 2015; 24(1): 8-14.
  11. Tiwari BP, Basu S. Estimation of sacroiliac joint index in normal subjects of various age groups: comparative evaluation of four different methods of quantification in skeletal scintigraphy. *Nucl Med Rev Cent East Eur.* 2013; 16(1): 26-30.
  12. Reyhan M, Özoğul S, Seydaoglu G. The Effects of Parity and Body Mass Index on the Quantitative Sacroiliac Joint Scintigraphy. *Turk J Nucl Med.* 2008; 17: 70-6.
  13. Lim ZW, Tsai SC, Lin YC, Cheng YY, Chang ST. A Worthwhile Measurement of Early Vigilance and Therapeutic Monitor in Axial Spondyloarthritis: A Literature Review of Quantitative Sacroiliac Scintigraphy. *EMJ Rheumatol.* 2021; 8(1):129-39.
  14. Abdelhai, SF, Abdelhamed, HM, El-Shafey, AM, Almolla RM. Quantitative scintigraphy in discriminating sacroiliac joint physiological and pathological uptake. *Egypt J Radiol Nucl Med.* 2020; 51:122.
  15. Bozkurt MF, Kiratli P. Quantitative sacroiliac scintigraphy for pediatric patients: comparison of two methods. *Ann Nucl Med.* 2014; 28(3): 227-31.
  16. Sebastjanowicz P, Iwanowski J, Piwowarska-Bilska H, Elbl B, Birkenfeld B. The reference of normal values of the sacroiliac joint index in bone scintigraphy. *Pomeranian J Life Sci.* 2016; 62(2): 52-5.
  17. Min HK, Kim HR, So Y, Chung HW, Lee SH. Semiquantitative analysis of sacroiliac joint to sacrum ratio of bone scintigraphy to predict spinal progression in early axial spondyloarthritis: a pilot study. *Clin Exp Rheumatol.* 2021; 39(3): 471-78.
  18. Yoon EC, Kim JS, Lim CH, Park SB, Park S, Lee KA, et al. Visual Scoring of Sacroiliac Joint/Sacrum Ratios of Single-Photon Emission Computed Tomography/Computed Tomography Images Affords High Sensitivity and Negative Predictive Value in Axial Spondyloarthritis. *Diagnostics (Basel).* 2023; 13(10): 1725.
  19. Ornilla E, Sancho L, Beorlegui C, Ribelles MJ, Aquerreta D, Prieto E, et al. Diagnostic value of quantitative SPECT/CT in assessing active sacroiliitis in patients with axial spondylarthritis and/or inflammatory low back pain. *An Sist Sanit Navar.* 2022; 45(1): e0953.
  20. Lee S, Jeon U, Lee JH, Kang S, Kim H, Lee J, et al. Artificial intelligence for the detection of sacroiliitis on magnetic resonance imaging in patients with axial spondyloarthritis. *Front Immunol.* 2023; 14: 1278247.
  21. Li H, Tao X, Liang T, Jiang J, Zhu J, Wu S, et al. Comprehensive AI-assisted tool for ankylosing spondylitis based on multicenter research outperforms human experts. *Front Public Health.* 2023; 11: 1063633.
  22. Bordner A, Aouad T, Medina CL, Yang S, Molto A, Talbot H, et al. A deep learning model for the diagnosis of sacroiliitis according to Assessment of SpondyloArthritis International Society classification criteria with magnetic resonance imaging. *Diagn Interv Imaging.* 2023; 104(7-8): 373-83.



## Revision of The Total Hip Arthroplasty Previously Placed False Acetabulum

### Yalancı Asetabulumuna Yerleştirilen Total Kalça Artroplastisinin Revizyonu

Mahmut KURTBOĞAN<sup>1</sup> , Cengiz IŞIK<sup>1</sup> , Cemal ALKAN<sup>1</sup> , Mahmut Timur TURHAN<sup>1</sup> 

<sup>1</sup>Bolu Abant İzzet Baysal University Medical School, Department of Orthopedics and Traumatology, Bolu, Türkiye

Geliş Tarihi (Received): 12.02.2024

Kabul Tarihi (Accepted): 24.04.2024

Yayın Tarihi (Published): 29.08.2024

#### Abstract

**Introduction:** The initial management of coxarthrosis is conservative modalities; the final treatment is total hip arthroplasty. It is essential to place the acetabular cup in the true acetabulum.

**Case report:** For a 43-year-old female patient, total hip replacement was performed, and it was seen that the acetabular cup was placed in the false acetabulum at a different medical center. Later, loosening of the prosthesis was detected, and revision total hip arthroplasty was performed about 26 months after the index surgery. The acetabular cup, previously placed in the false acetabulum, was left in place to act as a bone stock at the superior acetabulum. It was observed that there was no complication in the patient follow-up.

**Conclusion:** There is no femoral head that can be used as a graft to support the superior region of the true acetabulum in some revision cases. The acetabular cup, placed at the false acetabulum, can be used as an abutment in cases of aseptic loosening.

**Keywords:** Dysplastic Coxarthrosis, Revision Total Hip Arthroplasty, False Acetabulum, Surgery.

&

#### Öz

**Giriş:** Koksartrozun ilk tedavisi konservatif yöntemler olmasına rağmen nihai tedavi total kalça protezidir.

**Olgu:** 43 yaşında kadın hastaya dış merkezde total kalça protezi ameliyatı uygulanmış ve asetabular komponentin yalancı asetabulumuna yerleştirildiği görülmüştür. Daha sonra protezin gevşediği belirlendi ve ilk ameliyatından yaklaşık 26 hafta sonra revizyon total kalça artroplastisi yapıldı. Önceden yalancı asetabulumuna yerleştirilen asetabular komponent asetabulum superiorunda kemik stoğu görevi görmesi için yerinde bırakıldı. Hastanın takiplerinde herhangi bir komplikasyon izlenmedi.

**Sonuç:** Bazı revizyon vakalarında gerçek asetabulumun superior bölgesini desteklemek amacıyla greft olarak kullanılabilen femur başı yoktu, yalancı asetabulumuna yerleştirilen asetabular komponent de aseptik gevşeme vakalarında destek olarak kullanılabilir.

**Anahtar Kelimeler:** Displastik Koksartroz, Revizyon Total Kalça Protezi, Yalancı Asetabulum, Cerrahi.

**Atf/Cite as:** Kurtboğan M, Işık C, Alkan C, Turhan MT. Revision of The Total Hip Arthroplasty Previously Placed False Acetabulum. Abant Med J. 13(2):78-82. doi:10.47493/abantmedj.1223102

\*Sorumlu Yazar (Corresponding Author): Mahmut Kurtboğan, e-mail: kurtbogann@gmail.com



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

## Introduction

Developmental dysplasia of the hip (DDH) seen in infancy is the most common cause of secondary hip osteoarthritis in young patients (1). Although conservative treatment is the first step to managing dysplastic coxarthrosis, hip arthroplasty is the definitive treatment of pain and limitation of movement (2). Osteoarthritis patients secondary to developmental hip dysplasia (DDH) require total hip arthroplasty (THA) surgery at an earlier age than primary osteoarthritis patients. Surgery is more complex in these patients, and complication risk is higher than standard hip arthroplasties due to insufficient amount of acetabular bone, the disorder of the proximal femur anatomy, increased anteversion, muscle contractures, and limb length discrepancy (3).

In dysplastic coxarthrosis cases, the most crucial part of the surgery is acetabular reconstruction. Despite the superior placement of the acetabular component being accepted without lateral placement, it is recommended to place it in the true acetabulum as much as possible (3). Acceptable bone coverage is vital for adequate stability in placing the acetabular component in the true acetabulum (4). In Crowe type III and some types II and IV cases, the femoral head is used as an autograft for the insufficient superoposterior part of the acetabulum, or the acetabular component may need to be placed slightly above the true acetabulum (5). In cases where the acetabular component cannot be placed in the true acetabulum, the biomechanics of the hip will change significantly due to the change in the center of rotation of the hip, the durability of the reconstruction will be adversely affected, and this will cause premature loosening of the prosthesis (5).

The femoral head can be superiorly placed as a graft to support the acetabular component. The amount of the graft that covers the acetabular component should not exceed %40. (4). In this case, the previously placed acetabular component was left in place as an abutment since there was no femoral head. In the patient follow-ups, it was observed that the component placed in the false acetabulum acted as a support and remained stable.

## Case Presentation

This case report did not require approval by the ethical committee.

A 39-year-old female patient was diagnosed with DDH in infancy, and a spica cast was recommended as a treatment. The family refused the treatment and did not attend the follow-ups. In the last five years, pain in the right hip, especially at night time, and sleep disorder due to pain began to occur. The patient's resting pain started and gradually increased. As the patient's complaints did not regress and her complaints increased, the patient underwent primary total hip arthroplasty on 12.01.2015 at a different medical center. In this surgery, the patient's acetabular component was placed in the false acetabulum. The patient, who continued her active life after the surgery, did not have pain while walking, but the previous groin and hip pain continued during the resting period. In the first postoperative year, the patient started to have pain while walking and weight-bearing on the operated leg. When the patient was admitted to our hospital due to non-reducing pain, the physical examination revealed tenderness in hip movements and groin pain while walking. The patient was clinically unable to walk long distances, sometimes felt the need to use a cane, and had trouble sitting in a chair. The Harris hip score score was 51.1. On the posteroanterior (PA) pelvis radiograph, it was seen that the right hip acetabular component was placed in the false acetabulum, and there were minimal signs of osteolysis (Figure 1). Laboratory studies of the patient's blood sample resulted in C-reactive protein: 1.8 mg/L (N: 0-5), Sedimentation: 32 mm/h (N: 0-20), White blood cells: 4.4 K/uL (4.5-11.0). In the scintigraphy performed on 24.02.2017, it was reported that slightly increased activity uptake was detected in the superior portion of the acetabular component of the right hip prosthesis and trochanter major and minor, but these findings were not clear scintigraphic findings suggesting prosthesis infection/loosening. Since the patient's complaints continued and were not improved with medical treatment, revision total hip replacement surgery was performed, and the acetabular component was planned to be placed in the true acetabulum on 21.03.2017; the revision surgery was performed about 26 months after the index surgery.

On the first postoperative day, the patient was mobilized without any weight bearing. In-bed exercises and daily dressings were made. The patient was discharged on the fifth day because there were no complications in the postoperative period. On the 15th postoperative day, the sutures were removed at the outpatient follow-up. In the subsequent outpatient controls, it was observed that the patient's pain decreased, and her complaints

were improved. In the postoperative evaluation at the sixth month, the patient's pain decreased, and there was seldom pain. There was no need to use a cane; it was possible to sit in a chair. There was no limb incompatibility between both extremities preoperatively and postoperatively. There was no infective finding in place of the acetabular component, which was left in place during the intraoperative period. Acute phase reactants were normal both preoperatively and postoperatively. The walking distance had increased significantly, up to 10 times. The Harris hip score score was 85.55. The patient had no complaints in the 5th year following (Figure 2). No complications occurred.



**Figure 1.** Pelvis x-ray of postoperative 24th months after the total hip arthroplasty, osteolysis of the acetabular cup at first operation at different center



**Figure 2.** Pelvis x-ray of postoperative 5th years after the revision total hip arthroplasty



## Discussion

This case report is the first revision hip replacement surgery in the literature in which the old acetabular component is left in place.

One of the most technically challenging parts of arthroplasty in dysplastic coxarthrosis patients is to obtain a stable and long-lasting acetabular component that can be covered with sufficient bone tissue (4). Indication of total hip arthroplasty in coxarthrosis due to DDH patients is not different from that in primary coxarthrosis cases (6). In this respect, one of the situations that should be considered is where the acetabular bone support is the greatest, the true acetabulum, or the region around it (7). As we move proximally towards the iliac bone, the bone support weakens, and the risk of loosening the acetabular component increases (7). In patients with dysplasia, placing the acetabular component as medial to the true acetabulum as possible will reduce the moment arm of the body weight, thereby reducing the pressure on the acetabular component (8). In the 15-year follow-up, Linde et al. reported that the loosening rate was 13% in the acetabular components placed in the true acetabulum and 42% in those places in superiorly (3). In a study by Johnston et al., they found that the abductor muscles spend 116% more force during normal walking as a result of 20 mm proximal, 20 mm lateral, and 10 mm posterior placement of the hip center (3).

The support of the acetabular component with bone grafts was brought to the agenda by Dunn and Hess (8) and the femoral head was used as an autograft by Harris for support in cemented acetabular components. (9). In Harris' study series, although the union of the graft placed in the early period was observed, loosening rates of 20% at the end of the 7th year and 46% at the end of the 11th year were found (9). The reason for these loosening in the long term has been found to be the use of the sclerotic, cystic degenerated femoral head of the graft and the graft covering more than 40% of the acetabular component (10). Rodriguez, on the other hand, emphasized that the coverage rate of the acetabular component of the graft should be less than 40%, stated that the graft maintains its vitality and integrity, and noted that the main reason for loosening is the inadequacy of the cemented fixation rather than the collapse of the graft (10). In our case, due to the very few bone stocks between the false and true acetabulum, we did not remove the acetabular cup, previously placed in the false acetabulum, and provided superior support to the acetabular cup placed in the true acetabulum. By not using an extra autograft in this region, we prevented the resorption problem encountered in grafts. Thus, we forestalled the possibility of loosening the acetabular component due to graft resorption. Although there was no finding to suspect infection during the operation, we removed the polyethylene insert, which does not have any support function, so it does not constitute a source of infection.

Revision surgeries of patients with DDH who have undergone TKA are more challenging and have a higher risk of complications. Since there is no femoral head that can be used as a graft to support the superior region of the true acetabulum in these revision cases, the acetabular cup, placed at the false acetabulum, can be used as an abutment in cases of aseptic loosening.

**Informed Consent:** Written consent was obtained from the participants.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors declared no financial support.

**Author Contributions:** Idea/Concept: C.I, C.A, M.K, M.T.T.; Design: C.I, C.A, M.K, M.T.T.; Supervision: C.I.; Funding: C.I, C.A, M.K, M.T.T.; Materials: C.I, C.A, M.K, M.T.T.; Data Collection/Processing: C.I, C.A, M.K, M.T.T.; Analysis/Interpretation: M.K.; Literature Review: C.I, C.A, M.K, M.T.T.; Drafting/Writing: M.K.; Critical Review: C.I, C.A, M.K, M.T.T. The authors have accepted responsibility for the entire content of this manuscript and approved its submission.

## References

1. JH B. Congenital and Developmental of Anomalies of Hip and Pelvis, İn: Canale ST (ed). Campbell's Operative Orthopaedics. Ninth ed. Missouri, Mosby-Year Book Inc,1998:1021-60.
2. Sanchez-Sotelo, J., et al., Surgical treatment of developmental dysplasia of the hip in adults: I. Nonarthroplasty options. J Am Acad Orthop Surg, 2002;10(5):321-33.



3. SHI, Xiao-tong, et al. Preoperative planning for total hip arthroplasty for neglected developmental dysplasia of the hip. *Orthopaedic Surgery*, 2019; 11.3: 348-355.
4. Haddad FS, Masri BA, Garbuz OS, Duncan CP. Primary total replacement of the dysplastic hip. *J Bone Joint Surg* 1999; 81-A:1462-82.
5. Banaszkiwicz, P. A. Total hip replacement in congenital dislocation and dysplasia of the hip. In *Classic Papers in Orthopaedics*. London: Springer London. 2013;125-28
6. Harris WH: Total hip arthroplasty in the management of the congenital hip dislocation. In Callaghan JJ, Rosenberg AG, Rubash HE (eds): *The Adult Hip*. Lippincott-Rawen, Philadelphia 1998;1651-82.
7. Bicanic, Goran, et al. Current concept in dysplastic hip arthroplasty: Techniques for acetabular and femoral reconstruction. *World journal of orthopedics*, 2014; 5.4: 412.
8. Greber, Eric M., et al. Challenges in total hip arthroplasty in the setting of developmental dysplasia of the hip. *The Journal of arthroplasty*, 2017; 32.9: S38-44.
9. Hartofilakidis, George; Karachalios, Theofilos. Total hip arthroplasty for congenital hip disease. *JBJS*, 2004;86.2: 242-50.
10. Schofer, Markus D., et al. Reconstruction of the acetabulum in THA using femoral head autografts in developmental dysplasia of the hip. *Journal of Orthopaedic Surgery and Research*, 2011; 6: 1-7.



## Ceftazidime-induced Non-Convulsive Status Epilepticus (NCSE) in a pediatric patient with Literature Review

Pediyatrik Hastada Seftazidime Bağlı Nonkonvülsif Status Epileptikus (NKSE) Olgusu;  
Seftazidime Bağlı NKSE

Mehpare Sarı YANARTAŞ<sup>1\*</sup> , Sait AÇIK<sup>1</sup> , Özlem YAYICI KÖKEN<sup>1</sup> 

Gülşah AKSOY<sup>2</sup> , Şenay HASPOLAT<sup>1</sup> 

<sup>1</sup> Akdeniz University Medical Faculty, Department of Child Neurology, Antalya, Türkiye

<sup>2</sup> Akdeniz University Medical Faculty, Department of Child Nephrology, Antalya, Türkiye

Geliş Tarihi (Received): 19.03.2024

Kabul Tarihi (Accepted): 14.06.2024

Yayın Tarihi (Published): 29.08.2024

### Abstract

Cephalosporins are a class of antibiotics routinely prescribed for a variety of pediatric infections. Among uncommon adverse effects, cephalosporins can be neurotoxic and epileptogenic, particularly in patients with reduced renal function. Neurotoxic effects are most frequently observed in adults with impaired renal function, and they have rarely been recorded in children. An 11-year-old boy with chronic renal failure experienced non-convulsive status epilepticus two days after initiating intravenous cefazolin and ceftazidime with a pre-diagnosis of peritonitis. The patient's mental condition reverted to baseline within hours after intravenous antibiotic treatment was discontinued and appropriate antiepileptic and anticonvulsive therapy was started. Providers should investigate cephalosporin-induced non-convulsive status epilepticus clinically and electrophysiologically in any child with renal impairment who demonstrates acute changes in mental status or decreased awareness after initiating intravenous cephalosporins.

**Keywords:** Cephalosporin, Non-Convulsive Status Epilepticus, Renal Failure.

&

### Öz

Sefalosporinler, çeşitli pediyatrik enfeksiyonların tedavisinde rutin olarak reçete edilen bir antibiyotik sınıfıdır. Seyrek görülen yan etkiler arasında, sefalosporinlerin özellikle böbrek fonksiyonu azalmış hastalarda nörotoksik ve epileptojenik olabileceği belirtilmiştir. Nörotoksik etkiler, özellikle böbrek fonksiyonu bozulmuş yetişkinlerde daha sık gözlenirken, çocuklarda nadiren bildirilmiştir. Kronik böbrek yetmezliği tanısı ile takip edilen 11 yaşındaki erkek hastada peritonit ön tanısı ile intravenöz sefazolin ve seftazidim tedavisine başladıktan iki gün sonra non-konvülsif status epileptikus tablosu gelişmiştir. Hasta intravenöz antibiyotik tedavisinin kesilmesi ve uygun antikonvülsan tedavinin başlatılmasının ardından birkaç saat içinde mental durumu normale dönmüştür. İntravenöz sefalosporin başlanması sonrasında akut mental durum değişiklikleri gösteren her çocuk hastada klinik ve elektrofizyolojik olarak sefalosporin kaynaklı non-konvülsif status epileptikus akla gelmesi gereken ön tanılardan biridir.

**Anahtar Kelimeler:** Sefalosporin, Nonkonvulzif Status Epileptikus, Renal Yetmezlik.

**Atf/Cite as:** Sarı Yanartaş M, Açıık S, Yayıcı Köken Ö, Aksoy G, Haspolat Ş. Ceftazidime-Induced Non-Convulsive Status Epilepticus (NCSE) in a Pediatric Patient with Literature Review. Abant Med J. 13(2):83-91. doi:10.47493/abantmedj.1413064

\*Sorumlu Yazar (Corresponding Author): Mehpare Sarı Yanartaş, e-mail: mpiresari2@gmail.com



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

## Introduction

Cephalosporins are one of the most chosen classes of antibiotics for various types of infections because of their broad antibacterial spectrum and pharmacokinetic and pharmaco-dynamic features. Cephalosporins are classified into four generations according to their antibacterial ability. Neurotoxicity of cephalosporins was reported for all generations (1). While cephalosporin-related neurotoxicity can happen even with proper dose and during dialysis, predisposing variables include pre-existing central nervous system impairment, renal impairment, and excessive dosing (2).

Cephalosporin-related neurotoxicity can manifest as myoclonus, dystonic movements, tremor, asterixis, coma, seizure, encephalopathy, and status epilepticus. Non-convulsive status epilepticus (NCSE) is a rare but well-known side effect of cephalosporins in people with renal insufficiency (3). This disorder can result in varied degrees of altered consciousness in the absence of obvious motor signs. NCSE is defined as seizures that continue without convulsions for more than ten minutes without complete interictal recovery (4). The examination of an electroencephalogram (EEG) is essential for diagnosis of this illness, and EEG can reveal continuous or intermittent electrographic discharges. Here, we present a pediatric patient followed with renal failure and continuous ambulatory peritoneal dialysis (CAPD) who developed NCSE while being treated with intravenous cefazolin and ceftazidime for pre-diagnosis of peritonitis.

## Materials and Methods

### Case Report


An 11-year-old boy was brought to the outpatient clinic with complaints of fever, vomiting, and abdominal pain. He was diagnosed with chronic renal failure caused by posterior urethral valve. Since the patient had been receiving peritoneal dialysis for the previous six years, the current symptoms indicated peritonitis. He was hospitalized and administered intravenous cefazolin and intraperitoneal ceftazidime. During the fourth day of treatment, clinicians observed he was intermittently confused. At follow-up, he displayed a steady deterioration in his mental state, as well as disorientation and difficulty cooperating, occasionally featuring facial myoclonic jerks. He could be aroused, responded to queries, and obeyed directions at the time of the initial neurological evaluation. There were no focal neurological abnormalities found during the neurologic evaluation. Brisk deep tendon reflex and bilateral clonus were noted. His Glasgow Coma score was E4M6V4. Brain MRI showed periventricular white matter ischemic alterations (periventricular leukomalacia) in T1 series. Diffusion and SWI series were normal. His EEG (Figure-1) revealed constant 3-Hz bi/triphasic sharp waves, leading to the diagnosis of NCSE. After administering midazolam (0.1 mg/kg intravenously) and diazepam (10 mg intravenously), electrophysiological findings improved. He was treated with sodium valproate, which was initiated with loading dose of 20 mg/kg, intravenously and continued with oral maintenance therapy. His EEG background initially improved, nevertheless, throughout the course of the following hour, the persistent, widespread acute and slow wave activity reappeared. Intravenous levetiracetam and oral clonazepam were added as maintenance therapy because of the patient's intermittent drowsy state and EEG findings. As no alternate etiology for NCSE could not be identified, cephalosporin-induced NCSE was considered. Ceftazidime and cefazolin were discontinued, About two days after stopping the cephalosporin, clinical symptoms and EEG results improved. He was later discharged with full recovery. In the subsequent three months of follow-up, antiepileptic drugs were successfully discontinued and EEG results were entirely clear (Figure 2).

### Discussion

Here, we report a male with renal failure who had developed NCSE with the treatment of cephalosporins. As a differential diagnosis, we excluded if he had metabolic encephalopathy, severe hypertension, infectious diseases, and electrolyte imbalances which are the causes of altered consciousness in patients suffering from renal failure (5). His biochemical tests did not show electrolyte imbalance and, the renal function values were not increased compared to his baseline values. The blood pressure was at the 50th percentile for his age. During the NCSE period, the patient had been treated with antibiotics for peritonitis and, there was no increase in infectious biomarkers and he had no fever which is the main sign of the infections. However, since neurological deterioration occurred following antibiotic treatment, the lumbar puncture was planned to




exclude central nervous system infection by evaluating cerebrospinal fluid. However, the family did not consent to the procedure. The patient's EEG findings were consistent with NCSE. Clinical improvement was observed following the and the initiating antiepileptics and anticonvulsants and, discontinuation of the cephalosporins. This is proof that NCSE is related to cephalosporin treatment.



**Figure 1.** Preliminary electroencephalogram of the patient (during cephalosporin administration) suggestive of non-convulsive status epilepticus.

A)1st minute B) 5th minute C) 10 th minute D) 15 th minute



**Figure 2.** Control electroencephalogram – one week after discharge.

A)1st minute B) 5th minute C) 10 th minute D) 15 th minute

Neurotoxic adverse effects are caused by cephalosporins that can lead to status epilepticus, particularly NCSE, which is a well-known but unusual complication. Recent years have seen an increase in the number of reports

regarding the diagnosis of pediatric cephalosporin-induced NCSE. When a patient receives intravenous cephalosporin therapy and develops sudden changes in mental status, especially if they have any degree of renal failure, a diagnosis should be taken into consideration. It was reported that elderly patients are more likely to experience neurotoxicity since their creatinine clearance may decline with age. Here, we present a pediatric case with renal impairment diagnosed with NCSE, one of the neurotoxic effects of cephalosporins, while receiving intravenous cefazolin and intraperitoneal ceftazidime.

Cephalosporin-related neurotoxicity is thought to be associated with gamma aminobutyric acid (GABA)-A receptor antagonism because a part of the beta-lactam molecule resembles the chemical structure of the well-known GABA antagonist bicuculline (6,7). Inducing the release of endotoxins and TNF-alpha, which is associated with septic encephalopathy, and raising glutamate levels were considered as additional mechanisms contributing to neurotoxicity (8). Cefepime is the most frequently reported drug related to neurotoxicity among all generations of cephalosporins; however, ceftriaxone, ceftazidime, cefotaxime, and cefazolin were all cited. (8) It is common practice in acute peritonitis to administer a combination of first and third-generation cephalosporins, cefazolin and ceftazidime, intraperitoneally on an intermittent or continuous basis (8). The size of the substituents at positions 7 (R1) and 3 (R2) in their 7-cephalosporanic acid structures determines the epileptogenesis of cephalosporin. Positions 7 and 3 on a cefazolin heterocyclic ring may increase the possibility of epileptogenesis.

Prior central nervous system (CNS) disorders, high dosage consumption, and renal insufficiency are risk factors for cephalosporin-induced neurotoxicity (3). Patients suffering from renal insufficiency are more susceptible to neurotoxic effects because of changed pharmacokinetics that lead to raised blood urea nitrogen and cephalosporin concentrations in circulation. Additionally, the permeability of the blood-brain barrier is increased by glycosylated and carbamylated proteins (10). However, active peritonitis may raise membrane permeability and hence raise antibiotic absorption, raising the possibility of systemic toxicity (9). From the peritoneal cavity, ceftazidime is absorbed and enters the bloodstream. Compared to individuals who are not infected, patients with peritonitis absorb more medication from the peritoneal cavity (3). Despite being administered at authorized dosages, patients with renal impairment are more susceptible to ceftazidime neurotoxicity because the medication is not digested by the body and is eliminated unchanged in the active form in the urine by glomerular filtration (11). As a result of renal failure and peritonitis, our patient was in the risk group for cephalosporin neurotoxicity.

The onset of neurotoxicity can occur one to ten days later. After stopping cephalosporin medication, documented neurological problems frequently subside in two to seven days (1,12). The clinical condition of our patient worsened on the fourth day of cephalosporin medication. Symptoms began to improve two days after cephalosporin discontinuation.

Although NCSE was reported in patients with renal disease, neurotoxicity was also reported in cases without renal function problems (13). The diagnosis of drug-induced NCSE has become more common in recent years, and patients who experience sudden changes in their mental state while receiving intravenous cephalosporin treatment—especially those with some degree of renal dysfunction—should have this condition evaluated. An urgent EEG should be taken into account. The use of electroencephalography is necessary for precise diagnosis (4). Working criteria for the EEG diagnosis of NCSE were proposed by a consensus panel at the 4th London-Innsbruck Colloquium on status epilepticus and acute seizures, which was held in Salzburg in 2013 (Salzburg Consensus Criteria for Non-Convulsive Status Epilepticus, SCNC). Our patient was diagnosed with NCSE with continuous 3 Hz generalized spike and wave activity based on these criteria.

Myoclonic seizures, aberrant conduct, mutism, ataxia, asterixis, hallucinations, tremor, clonus, and hyperreflexia are among the clinical signs other than altered awareness that have been documented (6). Case reports have shown brief myoclonic seizures prior to NCSE, as was the situation with our patient (10).

Our case is an example of NCSE due to the neurotoxicity of cephalosporin at a therapeutic dosage in a pediatric patient with renal failure. It is important that this event should be considered in pediatric patients, although the majority of cases were reported at older ages. A summary of the previously reported pediatric patients with cephalosporin-induced NCSE is shown in Table 1. Most of the pediatric cases reported in the literature were related to cefepime. However, our case is significant due to its association with ceftazidime.



**Tablo 1.**

The Summary of Patients with The Diagnosis of Cephalosporin-Induced Non-Convulsive Status Epilepticus

References	Age of patient/ sex	Comorbidities	Drug	NCSE symptoms	Cranial imaging	EEG findings	Treatment	Follow up
<b>Chedrawi et al., 2004 (13)</b>	12-years/ Female	Chronic renal insufficiency secondary to congenital renal dysplasia.	ceftriaxone for possible sepsis	progressively more confused and unresponsive occasional myoclonic twitches of the face	CT: normal	Bursts and runs of generalized spike and spike wave discharges are recorded over a period of 90 seconds. Generalized triphasic and slow waves	diazepam , phenytoin,, benzodiazepine  Ceftriaxone was discontinued	the following day, mental status dramatically improved , became awake, coherent and able to follow verbal commands. complete resolution of the epileptiform discharges within 24 hours after discontinuing ceftriaxone background remained slow, likely a postictal effect.
<b>Alpay et al., 2004 (14)</b>	15years/Male	End-stage renal disease secondary to focal segmental glomerulosclerosis	intravenous cefepime for pneumonia	gait abnormality, difficulty in writing and reading, memory problems. progressive confusion	CT: did not show any acute abnormalities.  MRI : normal	consistent with status epilepticus	diazepam phenytoin  Cefepime therapy was discontinued	No neurological findings and with normal EEG (after 1 year follow-up)
<b>Thabet et al., 2009 (15)</b>	15-years / Female	End stage renal disease secondary to polycystic kidney on hemodialysis	IV cefepime for blood culture showed Pseudomonas aeruginosa	Lethargic and confused. (Glasgow coma scale of 8), myoclonic jerks	CT scan brain were unrevealing	Generalized spike and sharp wave activity compatible with NCSE	Midazolam continuous infusion.  İntubation  Cefepime was discontinued	the patient regained full consciousness (Glasgow coma scale of 15) after 48 hours  repeated EEG was normal



Nichols et al., 2011 (16)	A 15-year-old,	Cystic fibrosis kidney injury	Acute	IV cefepime for lower respiratory cultures contained MSSA and <i>Stenotrophomonas maltophilia</i> , with past cultures significant for <i>P. aeruginosa</i> .	Sleepy poorly responsive.	Not available	An electroencephalogram (EEG) was not obtained due to extubation of the patient	Hemodialysis	At a 2-week follow-up clinic visit, the patient was recovering well,
Landgrave et al., 2012 (17)	14 years / Female	McCune-Albright syndrome, hypoparathyroidism, asthma, hypogammaglobulinemia, factor V Leiden deficiency, deep vein thrombosis, worsening kidney failure during antibiotic treatment.		intravenous cefepime and meropenem for septic hip arthritis	deteriorated right-sided face twitching  sleeping, sedated	CT: mildly prominent lateral ventricles, with otherwise normal findings.	Requent, irregular, generalized polyspike wave discharges High-amplitude nonrhythmic slowing, and 2-second periods of background suppression or attenuation.  After pentobarbital infusion :burst suppression	midazolam drip levetiracetam.  pentobarbital infusion  Cefepime was discontinued  Meropeme was discontinued	
Ekici et al., 2012 (18)	Case1(C1): 15 years / Female  Case2 (C2): 7 years / Female	C1: Chronic renal failure who was on continuous ambulatory peritoneal dialysis (CAPD )  C2: Hypertension and chronic renal failure secondary to bilateral vesico-ureteral reflux		C1: Intraperitoneal and intravenous (IV) ceftazidime and vancomycin for peritonitis  C2: IV cefepime for open bilateral ureteroneocystostomy	C1: Headache, drowsiness, myoclonic jerks and ataxia.  C2: confused demonstrated inappropriate crying, agitation involuntary movements of the head and hands.	C1: (MRI) was normal.  C2: not available	C1: diffuse slow-spike waves and triphasic waves  C2: diffuse slow-spike waves	C1: ceftazidime was discontinued oral valproate  C2: cefepime was discontinued, iv diazepam , oral sodium valproate	C1: Began to communicate after 24 hours. Myoclonus disappeared (on the fifth day of treatment ) the EEG normalized after 6 days.  C2: symptoms were disappeared after 2days EEG findings were normalized after 10 days.

**Ceftazidime-induced Non-Convulsive Status Epilepticus (NCSE) in a pediatric patient with Literature Review**

<b>Shah et al. , 2021(19)</b>	13years/ Female	major depressive and behavioral disorder, focal segmental glomerulosclerosis, subsequent hemodialysis dependent end-stage renal diseases	intravenous cefepime for catheter infection	difficulty in walking and grasping items. aphasia visual hallucinations	CT: did not show any acute abnormalities.  MRI :unremarkable	mild background slowing, multifocal and diffuse epileptiform discharges, generalized excessive beta intermittently, slowing in the right posterior quadrant, left posterior quadrant, and central head regions	lorazepam levetiracetam phenobarbital  Cefepime therapy was discontinued  hemodialysis	back to her neurologic baseline with normal GCS within 24 hours
<b>Nguyen et al. 2022 (12)</b>	16 years/ Female	Chromosome 10-15 unbalanced translocation, spastic quadriplegic cerebral palsy, epilepsy, hydrocephalus with VP shunt, tethered cord syndrome  Tracheostomy fundoplication, scoliosis, and thoracic lordosis status post spinal fusion, and global developmental delay.	intravenous cefepime, linezolid and vancomycin for positive Escherichia coli urine cultures, positive Pseudomonas spp. respiratory cultures, Clostridium difficile prophylaxis	less responsive than usual Intermittent extensor posturing was noted with tactile stimuli,  no other response to noxious stimuli.	CT head : showed expected pneumocephalus with mild soft tissue swelling over the left frontal scalp	Rhythmic 2.5-3 Hz generalized epileptiform discharges	levetiracetam, lorazepam, phenobarbital  Cefepime was discontinued	Back to her baseline state of health within 2 days after discontinuing cefepime
<b>Hambrick et al., 2022 (20)</b>	2 years /	Chronic kidney diseases	IV cefepime for <i>Serratia marcescens</i> bacteremia	Agitation, tremor, and inconsolability	No data available  ( abstract only )	No data available  ( abstract only )	Cefepime was discontinued	No data available  ( abstract only )

In conclusion; while there are no defined standard criteria for the therapy of this condition have not been established, discontinuation of antibiotics, administration of antiepileptic drugs, and receiving supportive treatment are suitable measures to take. In this potentially curable illness, prompt detection and diagnosis are critical because protracted diagnostic delays may raise morbidity or death. Clinicians and doctors should be more aware of the possible neurotoxicity of ceftazidime and other cephalosporins because their usage is growing more widespread.

**Informed Consent:** Written consent was obtained from the participants.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors declared no financial support.

**Acknowledgement:** All authors thank the patient and his family for their participation in this report. Özlem Yayıcı Köken was supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1.

**Author Contributions:** Idea/Concept: M.S.Y., Ö.Y.K.; Design: M.S.Y., Ö.Y.K.; Supervision: M.S.Y., Ö.Y.K.; Funding: M.S.Y., Ö.Y.K.; Materials: Ö.Y.K., G.K.A., Ş.H.; Data Collection/Processing: M.S.Y., SA; Analysis/Interpretation: M.S.Y., SA; Literature Review: M.S.Y., SA, Ö.Y.K., Ş.H.; Drafting/Writing: M.S.Y., SA, Ö.Y.K., Ş.H.; Critical Review: M.S.Y., SA, Ö.Y.K., Ş.H. The authors have accepted responsibility for the entire content of this manuscript and approved its submission.

## References

1. Grill MF, Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. *Ann Pharmacother* 2008; 42(12): 1843–50. <http://doi.org/10.1345/aph.1L307>
2. Kim KB, Kim SM, Park W, Kim JS, Kwon SK, Kim HY. Ceftriaxone-induced neurotoxicity: case report, pharmacokinetic consideration, and literature review. *J Korean Med Sci* 2012; 27(9): 1120–1123. <http://doi.org/10.3346/jkms.2012.27.9.1120>
3. Bora I, Demir, AB, Uzun, P. Nonconvulsive status epilepticus cases arising in connection with cephalosporins. *Epilepsy Behav Case Rep* 2016; 6: 23-27. <http://doi.org/10.1016/j.ebcr.2016.04.005>
4. Hirsch LJ, Fong MWK, Leitinger M, LaRoche SM, Beniczky S, Abend NS et al. American Clinical Neurophysiology Society's Standardized Critical Care EEG Terminology: 2021 Version. *J Clin Neurophysiol* 2021; 38(1): 1-29. <http://doi.org/10.1097/WNP.0000000000000806>
5. Primavera A, Cocito L, Audenino D. Nonconvulsive status epilepticus during cephalosporin therapy. *Neuropsychobiology*. 2004;49(4):218-22. doi: 10.1159/000077370.
6. Vannaprasaht S, Tawalee A, Mayurasakorn N, Yodwut C, Bansong R, Reungjui S et al. Ceftazidime overdose-related nonconvulsive status epilepticus after intraperitoneal instillation. *Clin Toxicol (Phila)* 2006; 44(4): 383-6. <http://doi.org/10.1080/15563650600671753>
7. Wallace KL. Antibiotic-induced convulsion. *Crit Care Clin* 1997; 13(4): 741–762. [http://doi.org/10.1016/s0749-0704\(05\)70367-5](http://doi.org/10.1016/s0749-0704(05)70367-5)
8. Sugimoto M, Uchida I, Mashimo T, Yamazaki S, Hatano K, Ikeda F. Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins. *Neuropharmacology* 2003; 45(3): 304–314. [http://doi.org/doi:10.1016/s0028-3908\(03\)00188-6](http://doi.org/doi:10.1016/s0028-3908(03)00188-6)
9. Chen CC, Lee DJ, Lin SH. Reversible cefazolin-induced status epilepticus in a peritoneal dialysis patient. *Toxicol Rep* 2022; 9: 1950-1952. <http://doi.org/10.1016/j.toxrep.2022.10.011>
10. Al-Sadawi M, Rodriguez Ortega R, Sun N, Abdurahimova M, McFarlane SI. Jerky Movement with Ceftazidime: A Case of Ceftazidime-Induced Neurotoxicity with a Review of the Literature. *Case Rep Med* 2019. 8936478. <http://doi.org/10.1155/2019/8936478>
11. Ong CY, Qin Y. Myoclonus from Antibiotic Therapy (Ceftazidime-induced Neurotoxicity): A Case Report and Review. *Cureus* 2018; 10(3): e2250. <http://doi.org/10.7759/cureus.2250>
12. Roncan-Albuquerque R, Pires I, Martins R, Real R, Sousa G, Von Hafe P. Ceftriaxone-induced acute reversible encephalopathy in a patient treated for a urinary tract infection. *Neth J Med* 2009; 67(2): 72-75.

13. Nguyen C, Clegg T, Kumar A, Paudel S. Cefepime-Induced Nonconvulsive Status Epilepticus in a Pediatric Patient with Normal Renal Function. *Child Neurol Open* 2022; 7: 9:2329048X221119575. <http://doi.org/10.1177/2329048X221119575>
14. Chedrawi AK, Gharaybeh SI, Al-Ghwery SA, Al-Mohameed SA, Alshahwan SA. Cephalosporin-induced nonconvulsive status epilepticus in a uremic child. *Pediatr Neurol.* 2004 Feb;30(2):135-9. doi: 10.1016/j.pediatrneurol.2003.07.006.
15. Alpay H, Altun O, Biyikli NK. Cefepime-induced non-convulsive status epilepticus in a peritoneal dialysis patient. *Pediatr Nephrol.* 2004 Apr;19(4):445-7. doi: 10.1007/s00467-003-1333-8
16. Thabet F, Al Maghrabi M, Al Barraq A, Tabarki B. Cefepime-induced nonconvulsive status epilepticus: case report and review. *Neurocrit Care.* 2009;10(3):347-51. doi: 10.1007/s12028-008-9166-8
17. Nichols, K. R., Brown, D. M., Knoderer, C. A., & Andreoli, S. P. (2011). Cefepime Neurotoxicity in an Adolescent Cystic Fibrosis Patient with Aminoglycoside-Induced Acute Kidney Injury. *Journal of Pharmacy Technology*, 27(4), 164–167. doi:10.1177/875512251102700404
18. Landgrave LC, Lock JL, Whitmore JM, Belcher CE. Pediatric cefepime neurotoxicity. *Pediatr Neurol.* 2012 Dec;47(6):458-60. doi: 10.1016/j.pediatrneurol.2012.08.017.
19. Ekici A, Yakut A, Kural N, Bör Ö, Yimenicioğlu S, Çarman KB. Nonconvulsive status epilepticus due to drug induced neurotoxicity in chronically ill children. *Brain Dev.* 2012 Nov;34(10):824-8. doi: 10.1016/j.braindev.2012.02.004.
20. Shah S, Bland S. Cefepime-Induced Encephalopathy With Seizures in a Pediatric Patient With End-Stage Renal Disease Rapidly Reversed by High-Efficiency Hemodialysis. *Cureus.* 2021 Mar 12;13(3):e13842. doi: 10.7759/cureus.13842.
21. Hambrick HR, Pavia K, Tang Girdwood S, Lazear D, Taylor JM, Benoit S. Cefepime-Associated Neurotoxicity in a Pediatric Patient With Stage V Chronic Kidney Disease. *J Pharm Pract.* 2022 Sep 8:8971900221125000. doi: 10.1177/08971900221125000.



## A Case Report: Lipomatous Hypertrophy of the Interatrial Septum

Olgu Sunumu: İnteratriyal Septumun Lipomatöz Hipertrofisi

Ayşenur Buz YAŞAR<sup>1\*</sup> , Sıddıka HALICIOĞLU<sup>1</sup> 

<sup>1</sup>Bolu Abant İzzet Baysal University, Research and Training Hospital, Department of Radiology, Bolu, Türkiye

Geliş Tarihi (Received): 09.05.2024

Kabul Tarihi (Accepted): 10.07.2024

Yayın Tarihi (Published): 29.04.2024

### Abstract

Lipomatous hypertrophy of the interatrial septum is a benign condition characterized by the deposition of fat into the interatrial septum. It is often mistaken for atrial masses and can be associated with conditions such as obesity, and steroid use. In this case presentation, we describe the computed tomography (CT) findings of an incidentally detected and asymptomatic case of lipomatous hypertrophy of the interatrial septum in an 81-year-old male patient with a history of nephrolithiasis. The patient underwent CT imaging, revealing a nodular thickening of the interatrial septum. Despite the presence of moderate cardiomegaly, the patient did not exhibit any symptoms related to the cardiac mass. Lipomatous hypertrophy of the interatrial septum is often asymptomatic but can rarely cause cardiac symptoms and arrhythmias. Differential diagnoses include other cardiac masses. Accurate diagnosis is crucial to avoid unnecessary surgery and to provide appropriate management. Diagnostic assessment involves multiple imaging modalities, such as echocardiography, cardiac CT, and magnetic resonance imaging (MRI) scans, with CT and MRI being particularly useful in characterizing the tissue properties. The recognition and understanding of lipomatous hypertrophy of the interatrial septum are important for radiologists to ensure accurate diagnosis and appropriate patient management.

**Keywords:** Lipomatous Hypertrophy Of The Interatrial Septum, Atrial Mass, Computed Tomography.

&

### Öz

İnteratriyal septumun lipomatöz hipertrofisi, interatriyal septumda yağ birikmesiyle karakterize benign bir durumdur. Sıklıkla atriyal kitlelerle karıştırılır ve obezite, steroid kullanımı gibi durumlarla ilişkilendirilebilir. Bu vaka sunumunda, 81 yaşında, nefrolitiazis öyküsü olan bir erkek hastada, rastlantısal olarak tespit edilen ve semptomsuz interatriyal septumun lipomatöz hipertrofisinin bilgi-sayarlı tomografi bulgularını sunacağız. Hastaya yapılan BT görüntülemesinde interatriyal septumda nodüler kalınlaşma tespit edildi. Hastanın orta derece kardiomegali dışında, kardiyak kitle ile ilişkili herhangi bir semptomu yoktu. İnteratriyal septumun lipomatöz hipertrofisi genellikle semptomsuzdur ancak nadiren kardiyak semptomlara ve aritmilere neden olabilir. Ayırıcı tanı diğer kardi-yak kitleleri içerir. Gereksiz cerrahi önlemek ve uygun hasta yönetimini sağlamak için doğru tanı konulması hayati öneme sahiptir. Tanıda ekokardiyografi, kardiyak BT ve manyetik rezonans görüntüleme (MRG) gibi çeşitli yöntemleri içerir; BT ve MRG, dokunun özelliklerini karakterize etmede özellikle yararlıdır. İnteratriyal septumun lipomatöz hipertrofisinin tanınması ve anlaşılması, doğru tanı konulması ve uygun hasta yönetimini sağlamak için radyologlar için önemlidir.

**Anahtar Kelimeler:** İnteratriyal Septumun Lipomatöz Hipertrofisi, Atriyal Kitle, Olgu Sunumu, Bilgisayarlı Tomografi.

**Atıf/Cite as:** Buz Yaşar A, Halicioğlu S. A Case Report: Lipomatous Hypertrophy of the Interatrial Septum. Abant Med J. 13(2):92-95. doi:10.47493/abantmedj.1481469

\*Sorumlu Yazar (Corresponding Author): Ayşenur Buz Yaşar, e-mail: aysenurbuz@gmail.com



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.




## Introduction

Lipomatous hypertrophy of the interatrial septum is an entity was described in autopsy examinations in 1964 (1). It is characterized by non-capsulated, dumbbell-shaped infiltration of fatty tissue in the interatrial septum (2,3). To be considered lipomatous hypertrophy of the interatrial septum, the septum must reach a thickness of over 20 mm while preserving the fossa ovalis (4). With the frequent use of echocardiography, cardiac computed tomography (CT) imaging, and magnetic resonance imaging (MRI), it is increasingly recognized and tissue characterization can be done more clearly (1,3). In this case presentation, we aimed to increase awareness of this condition among radiologists by sharing an CT findings of incidentally detected and remained asymptomatic case of lipomatous hypertrophy of the interatrial septum, which can be mistaken for atrial masses. In this case presentation, we aim to raise awareness among radiologists about lipomatous hypertrophy of the interatrial septum by sharing CT findings of an incidentally detected and asymptomatic case. This condition can be mistaken for atrial masses.

## Case Presentation

Written informed consent was obtained from the participant for publication of medical records and images of the patient. An 81-year-old male patient with a history of nephrolithiasis underwent further evaluation with non-contrast and contrast enhanced CT imaging during his visit to the urology clinic due to macroscopic hematuria. The patient underwent extracorporeal shock wave lithotripsy (ESWL) in 2015 due to kidney stones. Abdominal CT scan is revealed a 12 mm stone in the right ureter at the constriction at pelvic brim and an atrophic right kidney. Urogram phase was delayed at the right kidney. Due to advanced age of the patient, he was recommended to be monitored for the ureteral stone. At the same time, a nodular thickening reaching 24 mm diameter with increased fat density at the level of the interatrial septum drew attention on the chest included in this examination (Figure). The patient had moderate cardiomegaly and did not exhibit any accompanying symptoms related to cardiac mass during cardiac examination and an electrocardiogram showed sinus rhythm.



**Figure 1.** Axial and multiplanar views of lipomatous hypertrophy of the interatrial septum on computerized tomography (CT) images. (A-C) Axial CT images, these images show the presence of fat density (low attenuation) within the interatrial septum. The yellow arrows indicate areas where the fat density is causing a mass effect on the adjacent cardiac structures. (D) Sagittal CT view provides a longitudinal perspective of

the heart, illustrating the extent of the lipomatous hypertrophy. (E) Coronal CT view is particularly useful for assessing the vertical extent and impact of the hypertrophy on the atrial chambers.

## Discussion

Lipomatous hypertrophy of the interatrial septum is a finding characterized by adipose tissue infiltration in the interatrial septum, which is believed to be associated with conditions such as obesity, steroid use, and emphysema, and is more commonly seen in women and older age groups (3). Although the incidence of lipomatous hypertrophy is not exactly known, the reported incidence in the literature varies between %1 to 8 (2,5). While lipomatous hypertrophy of the interatrial septum is a benign condition, it is important for radiologists to be aware of this entity to prevent unnecessary surgery and exaggerated diagnoses, as its differential diagnosis includes tumors such as lipoma, liposarcoma, myxoma, metastasis, rhabdomyoma, fibroma, and iatrogenic hematoma in cases with previous history of percutaneous coronary interventions. Recognizing this entity is important as it can be mistaken for atrial masses (4). Although lipomatous hypertrophy of the interatrial septum is mostly asymptomatic, when they originate from the atria, they can rarely cause premature atrial contractions, dyspnea, chest discomfort, right atrial obstruction, or even sudden cardiac death (4,5,6). The underlying mechanism of arrhythmia is not clear but there are hypotheses have been suggesting as a result of involvement of interatrial septum and right atrial wall which may distort the structure and conducting pathways (2,7). Surgical interventions like removal of the lipomatous mass or septal myectomy may be considered in severe cases with significant hemodynamic impairment or malignant arrhythmias (7). Diagnostic assessment of lipomatous hypertrophy of the interatrial septum involves multiple imaging modalities including echocardiography, cardiac CT or MRI scans. The initial evaluation often start with an echocardiography exam which provides valuable information regarding the location and size of the lesion, however it is not always possible to differentiate fat from the connective tissue on echocardiography. The initial evaluation often starts with an echocardiography exam, which provides valuable information regarding the location and size of the lesion. However, it is not always possible to differentiate fat from connective tissue on echocardiography (2,7). Therefore for further characterization of the tissue characteristics the role of cardiac CT and MRI is critical. Sparing of the fossa ovalis gives the lesion typical dumbbell-shaped appearance which makes the diagnosis easier (2).

The initial evaluation often starts with an echocardiography exam, which provides valuable information regarding the location and size of the lesion. However, it is not always possible to differentiate fat from connective tissue on echocardiography.

## Conclusion

Lipomatous hypertrophy of the interatrial septum is a relatively common, usually asymptomatic, benign condition that may mimic interatrial masses. The diagnosis is more frequently and easily made nowadays with the accelerating use of multimodality imaging techniques in which we are able to characterize tissue properties in daily clinical practice.

### List of Abbreviations

CT: Computed Tomography

MRI: Magnetic Resonance Imaging

ESWL: Extracorporeal Shock Wave Lithotripsy

**Informed Consent:** Written consent was obtained from the participants.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors declared no financial support.

**Author Contributions:** Idea/Concept: A.B.Y.; Design: A.B.Y.; Supervision: S.H.; Funding: A.B.Y., S.H.; Materials: A.B.Y., S.H.; Data Collection/Processing: A.B.Y., S.H.; Analysis/Interpretation: S.H.; Literature Review: S.H.; Drafting/Writing: A.B.Y.; Critical Review: A.B.Y., S.H. The authors have accepted responsibility for the entire content of this manuscript and approved its submission.

## References

1. O'Connor S, Recavarren R, Nichols LC, Parwani AV. Lipomatous hypertrophy of the interatrial septum: An overview. *Archives of Pathology & Laboratory Medicine*. 2006 Mar 1;130(3):397–9. doi:10.5858/2006-130-397-lhotis
2. Lampropoulos KM, Kotsas D, Iliopoulos T. Lipomatous hypertrophy of interatrial septum. *BMJ Case Reports* [Internet]. 2012 Sep 21;2012(sep20 1):bcr2012006611. Available from: <https://doi.org/10.1136/bcr-2012-006611>
3. Gopal DJ, Han Y, Silvestry FE, Ferrari VA. Atypical presentation of lipomatous hypertrophy of the interatrial septum: a case report. *European Heart Journal Case Reports* [Internet]. 2019 Nov 11;3(4):1–4. Available from: <https://doi.org/10.1093/ehjcr/ytz202>
4. Stojanovska J, Attili AK. AJR Teaching File: Fat-Containing Mass in the interatrial septum. *American Journal of Roentgenology* [Internet]. 2010 Dec 1;195(6\_supplement):S73–S75. Available from: <https://doi.org/10.2214/ajr.09.7173>
5. Bielicki G, Lukaszewski M, Kosiorowska K, Jakubaszko J, Nowicki R, Jasinski M. Lipomatous hypertrophy of the atrial septum – a benign heart anomaly causing unexpected surgical problems: a case report. *BMC Cardiovascular Disorders* [Internet]. 2018 Jul 28;18(1). Available from: <https://doi.org/10.1186/s12872-018-0892-3>
6. Güler A, Karakoyun S, Sahin A, Yıldız M. Interatrial septal mass. *Anadolu Kardiyoloji Dergisi/Anadolu Kardiyoloji Dergisi* [Internet]. 2013 Sep 17; Available from: <https://doi.org/10.5152/akd.2013.223>
7. Xanthopoulos A, Giamouzis G, Alexopoulos N, Kitai T, Triposkiadis F, Skoularigis J. Lipomatous hypertrophy of the interatrial septum: A case report and Review of the literature. *CASE* [Internet]. 2017 Oct 1;1(5):182–189. Available from: <https://doi.org/10.1016/j.case.2017.06.005>



# Abant Medical Journal

